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Axon (Wallerian) degeneration, an early event preceding neuronal loss in neurodegenerative 
disease and traumatic brain injury, is the active process of dismantling the axon. Degeneration of 
the cytoskeleton occurs through the protease activity of calpains, which are activated by a 
characteristic late rise in intra-axonal calcium following axonal injury (execution phase). The 
increase in calcium may be influenced by the signature disruption of energy homeostasis in 
Wallerian degeneration; however, defining this relationship and the progression of the execution 
phase remains to be established. Recently, studies demonstrated that the executioner protein 
SARM1 performs NADase activity resulting in the generation of cyclic ADP-ribose. This novel 
SARM1 enzymatic activity may bridge the gap in understanding the relationship between these 
two events. Here, we use a computational model to investigate the relationship between energy 
state and intra-axonal calcium influenced by the enzymatic activity of SARM1. We have defined 
a mechanistic model that incorporates the cleavage products and can predict the effects on the 
temporal release of calcium from intracellular stores and monitor ATP and NAD concentrations. 
Construction of the mathematical model is based on Biochemical Systems Theory (BST), which 
has been applied successfully in predicting outcomes of neurodegenerative diseases. MATLAB 
analyzes the biochemical reactions represented as ordinary differential equations (ODEs) and 
allows for perturbations of the system to mimic experimental interventions. In our model, we 
have gathered data demonstrating a depleted energy state and altered calcium concentration from 
SARM1’s NADase activity promotes degeneration in axons. By comparing these data to results 
from axotomized primary neuronal cultures, we can assess the plausibility of the proposed 
mechanism occurring in vitro. The process of active degeneration in axons is complex and the 
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use of a computational model representing the degeneration pathway will help elucidate its 
mechanisms and possibly provide insight for development of future therapeutic targets. 
1. Introduction 
 Axon (Wallerian) degeneration is a highly conserved, self-destruction pathway that 
functions to dismantle injured axons in both the central and peripheral nervous systems in a 
synchronous fashion. This degeneration is an early event preceding neuronal loss in 
neurodegenerative disease and traumatic brain injury and is the main driver of pathology in 
peripheral neuropathies. Therefore, understanding the mechanisms of axon degeneration is of 
utmost importance due to its prevalence in a wide array of neurological disorders and injuries. 
 The mechanisms of Wallerian degeneration remain poorly understood. However, this 
process can be modeled experimentally through the disruption of axonal transport (e.g. axon 
transection, crush, vincristine treatment) or energy deprivation.  Wallerian degeneration has been 
characterized by the fragmentation of the distal axons to the site of injury after a characteristic 
lag time, termed the latent phase. This latent phase lasts for 36 to 44 hours in mouse sciatic nerve 
and about 3 hours in primary retinal ganglion cell culture from zebra finch embryos (Beirowski 
et al., 2005).  
The spontaneous Wlds mutation in mice led to major insight into the degenerative 
process by providing a means to assess if axonal loss in various diseases is related to Wallerian 
degeneration. WLDs is a chimeric protein, with the 70 amino acids of the N-terminus being the 
same as the N-terminus of Ube4b and the amino acids of the C-terminus containing the full 
length of nicotinamide mononucleotide adenylyl transferase 1 (Nmnat1). Ube4b is an ubiquitin-
ligase and Nmnat1 is an enzyme that synthesizes NAD from nicotinamide mononucleotide 
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(NMN) and ATP. Transected axons in the sciatic nerve of mice expressing WLDs are protected 
for over two weeks, whereas transected axons in wild type mice survive for about 1.5 days 
(Mack et al., 2001; Sasaki, 2009; Milde, Freeman, & Coleman, 2013; Yahata et al., 2009; 
Babetto et al., 2010). Experiments disrupting the enzymatic activity of the Nmnat1 domain in 
WLDs demonstrate that Nmnat1 is crucial for the protection against axon degeneration. Axons 
expressing WLDs with a loss of function mutation of the Nmnat1 domain show survival 
comparable to wild type axons (Conforti et al., 2009). Although the Nmnat1 isoform is localized 
to the nucleus, the protective action of WLDs has been shown to be outside of the nucleus 
(Cohen et al., 2012; Sasaki, & Milbrandt, 2010; Conforti et al., 2009). Overexpression of other 
Nmnat isoforms also demonstrate protective action against axonal degeneration in non-nuclear 
locations (Yahata et al., 2009; Sasaki, & Milbrandt, 2010; Conforti et al., 2007). Overall, the 
spontaneous mutation of Wlds led to the appreciation of axon degeneration as an active, 
regulated process. 
The proposed mechanism of axonal protection mediated by WLDs is mimicking the 
function of the endogenous protein Nmnat2, which is lost in disruption of axonal transport by 
injury. Removal of Nmnat2 causes uninjured axons to undergo axonal degeneration, which can 
be rescued by WLDs expression (Gilley et al., 2013; Gilley, & Coleman, 2010; Hicks et al., 
2012). Although WLDs expression and increased Nmnat activity prevent early declines in ATP 
in the distal axon, neither increase NAD in injured axons compared to healthy, wild type axons, 
which is counterintuitive to the enzymatic function of Nmnat (Sasaki, Araki, & Milbrandt, 2006; 
Wang et al., 2005; Coleman, & Conforti, 2014; Wang, & He, 2009). Furthermore, inhibiting 
NAD consuming enzymes, such as PARP1 and CD38, to increase intra-axonal NAD 
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concentrations do not confer axonal protection (Sasaki et al., 2009). Therefore, it remains unclear 
if NAD is the protective product generated through Nmnat enzymatic activity.  
There are two phases in Wallerian degeneration referred to as the initiation phase and the 
execution phase. An established part of the Wallerian degeneration pathway is a disruption of 
calcium homeostasis in the distal axon after injury (Yang et al., 2013; George, Glass, & Griffin, 
1995; Zhai et al., 2003; Adalbert et al., 2012; Ma et al., 2013). This disruption occurs during the 
execution phase, which is downstream of Nmnat loss, NAD depletion, and depolarization due to 
energy failure (Coleman, & Conforti, 2014; Yang et al., 2013; Adalbert et al., 2012; Mishra et 
al., 2013; Gerdts et al., 2015). Large increases in cytosolic calcium cause calcium sensitive 
proteases, such as calpains, to activate and degrade cytoskeletal components of the distal axon 
(George, Glass, & Griffin, 1995).  
There are two phases of calcium rises following axonal transection termed the early and 
late calcium increases, respectively. The early calcium increase follows immediately after axonal 
injury due to the opening left from the transection. Calcium homeostasis is quickly reestablished 
and a lag phase follows where there is no observable evidence of axon degeneration. Previously, 
it was shown that the expression of WLDs did not change this early calcium influx (Vargas et al., 
2015). Additionally, inducing multiple early calcium increase events through multiple axon 
transections did not alter the time course of degeneration. Although there is degeneration in the 
early phase in both the distal and proximal axons nearest to the injury site, this early rise in 
calcium is not necessary for Wallerian degeneration (Vargas et al., 2015).  
However, late phase calcium increase is required for Wallerian degeneration to take place 
in the distal axon. This late rise in calcium is seen at the end of the lag phase, immediately before 
degeneration (Vargas et al., 2015). Additionally, this late increase depends on extracellular 
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calcium since chelating extracellular calcium protected injured axons from degeneration (Mishra 
et al., 2013). The injury induced depolarization from energy failure in the distal axon causes L-
type voltage gated calcium channels (VGCCs) to open allowing the influx of extracellular 
calcium (Mishra et al., 2013; Shen et al., 2013). Extracellular calcium influx through these 
channels is known to induce cellular pathways that trigger the release of calcium from 
intracellular stores, such as activation of the ryanodine and IP3 receptors. Furthermore, the 
removal of calcium from intracellular stores mediated a similar delay in axonal fragmentation, 
which confirms the involvement of intracellular release of calcium in this late rise (Villegas et 
al., 2014). Injured axons expressing WLDs do not demonstrate this late rise of calcium and were 
protected from degeneration (Avery et al., 2012). However, the prevention of extracellular 
calcium influx by blocking VGCCs only delays the late calcium rise, and thus confers moderate 
axonal protection (Bramley et al., 2016; George, Glass, & Griffin, 1995). Such observations 
indicate that alternative mechanisms may be releasing calcium from intracellular stores to 
account for the late rise in calcium of the distal axon. 
Although the initiators of this pathway remain unknown, the sterile alpha and TIR motif 
containing 1 (SARM1) protein is necessary in propagating axonal degeneration (Gerdts et al., 
2013; Gerdts et al., 2015). Knockout animal models of SARM1 demonstrate protection of 
injured axons comparable to protection mediated by WLDs (Osterloh et al., 2012). However, it is 
still unclear what causes the activation of SARM1 in distal axons after injury and whether 
SARM1 is involved in the initiation or executions phases of axon degeneration. Until recently, 
the enzymatic function of SARM1 also remained elusive. Work by Essuman et al. (2017) 
demonstrated SARM1 as a NAD consumer that generates the products cyclic ADP-ribose 
(cADPR), ADP-ribose (ADPR), and Nam. Here, a potential mechanism for this novel enzymatic 
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activity of SARM1 in Wallerian degeneration is proposed by using a testable mathematical 
model (see Appendix for full figure). Two hypotheses are investigated: (i) due to cytosolic 
calcium rises in spite of L-type VGCC blockage, ADPR and cADPR generated from SARM1 
NADase activity may be sufficient in contributing to significant cytosolic calcium accumulation 
for degeneration to proceed following injury, and (ii) SARM1’s NADase activity may contribute 
to the characteristic energy failure observed in Wallerian degeneration through depleting NAD 
and promoting cytosolic calcium accumulation. The model incorporates the generation of 
SARM1’s cleavage products and predicts their effects on calcium and energy homeostasis in 
injured axons to provide insight into the progression of degeneration. 
2. Methods  
 Here, methods for axon degeneration for zebra finch retinal ganglion cell (RGC) assays 
are presented and major pathways contributing to the pathology of axon degeneration are 
outlined. These biochemical pathways were represented visually using the program 
CellDesigner. In the accompanying models, arrows indicate transitions between species and 
states. Species with a (*) indicate the active form of the species. Modulation of reactions is 
represented with an open circle for catalysis and a hard edge for inhibition. Formation of 
complexes was considered reversible unless otherwise indicated. A full version of the model may 
be found in the Appendix.  
2.1 Axon Degeneration Assay (Embryonic Zebra Finch RGC) 
The following methods were described previously in Bramley et al. (2016), where I was cited 
in the Acknowledgements. Specific changes to the methods employed in my experiments on 
neuronal cultures are included where appropriate. 
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Plate coating  
Neurons were cultured on 24-well plates (Falcon 353047, Fishersci, Pittsburgh, PA). The 
plates were coated in preparation for cell culture with 10 μg/ml poly-d-lysine (Sigma P7886, St 
Louis, MO), refrigerated overnight, and then rinsed with water three water washes. These plates 
were then coated with 10 μg/ml laminin (LifeTech 23017-015, Carlsbad, CA) and incubated 
overnight at 37 °C. Before explants were added, the laminin was removed and allowed to dry for 
five minutes.  
Primary neuronal culture  
All animal work was approved by the William & Mary IACUC (IACUC-2017-03-18-
11976-wjBramley "Neurodegeneration in Songbirds"). Staging was determined using the 
established staging guide that aligns zebra finch (Taeniopygia guttata) development with classic 
chick development (Murray et al., 2013). Retinal explants containing retinal ganglion cells 
(RGCs) were dissected from eight day-old embryonic zebra finch eggs. Dissection methods 
established in chickens were applied here to zebra finches (Bronner-Fraser, 1996). Retinas were 
obtained by removing the eyes of the chick and peeling away the outer epithelium layers in 
phosphate-buffered saline (PBS). The retinas were then placed in their own separate wells of L-
15 (Thermo Fischer Scientific 21083027, Waltham, MA) where the pigment layer was removed. 
The retina was then divided into explants using fine forceps and pipetted onto the laminin plates.  
Following dissection, the plated retinal explants were incubated at 37 °C in a low volume 
of DMEM + 10 % FBS (Gibco Invitrogen, Carlsbad, CA) to promote adherence to the tissue 
culture plate. After this initial incubation, RGC explants were grown in 500 μL DMEM/FBS 
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supplemented with nerve growth factor (Sigma n0513, St Louis, MO) for five days in vitro and 
inspected for sufficient axon length before experimentation and imaging.  
Physical axon injury  
Axotomy served as the physical injury. Axotomy was administered to cultured RGCs 
using a stainless steel blade (Fine Science Tools, 10035-10, Foster City, CA). The cut was made 
in close proximity to the explant, and cells were incubated at 37 °C for 15 or 24 hours. After 15 
or 24 hours, the cells were fixed in 10% PFA (Electro Microscopy Sciences 15714-S) for 10 
minutes followed by two 1x PBS washes. The degeneration inhibitor Nifedipine (Sigma N7634, 
St Louis, MO) was used in experiments immediately following axotomy at 3 µM, 6 µM, and 18 
µM treatments. 
Fluorescence microscopy  
Fixed neurons were stained with CellMask Orange Plasma membrane stain (Life 
Technologies, C10045, Carlsbad, CA). Cells were incubated with the stain for 10 min at 37 °C. 
Images were acquired immediately after staining using a scanning confocal microscope (Nikon 
Ti Microscope with A1 Confocal). Nine images of each explant were acquired (using the ‘3 × 3 
large image’ settings).  
In separate experiments to uncover the time course of axon degeneration, live cells were 
placed in a live-cell chamber suspended in imaging media (FluoroBrite DMEM A18967, Life 
Technologies, Carlsbad, CA) for time-lapse imaging. 
Image analysis  
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Fragmentation of the axons was detected and quantified Using NIH ImageJ (FIJI). The 
quantitative measure resulting from this analysis is the degeneration index (DI), where 1 is 
completely degenerated and 0 is fully intact adapted from Gerdts et al. (2011). The data set was 
imported into the visualization program Spotfire (Tibco, Palo Alto, CA). The acquired images 
were then quality controlled to determine if they were in focus and contained axons. If images 
did not meet these criteria, they were removed from the final statistical analysis. There were 3 
replicates considered. The DI for each explant well is the average of the image tiles comprising 
the well. DIs of wells on the same plate receiving the same treatment were then averaged to 
obtain the final DI for the corresponding replicate. 
2.2 Depolarization in Response to Injury 
2.2.1 Inhibition of voltage gated calcium channels via nifedipine treatment 
 Following axonal injury, a depleted energy state leads to hindered function of the Na+/K+ 
ATPase (Stys et al., 1992; Wang et al., 2012). Without the constant separation of these ions, 
resting membrane potential cannot be maintained and the axon becomes depolarized through 
sodium and potassium currents. Depolarization through the interplay of these currents allows for 
opening of L-type voltage gated calcium channels (VGCCs) and a means for extracellular 
calcium to flood into the axon (Lipscombe, Helton, & Xu, 2004; Moldovan, Alvarez, & Krarup, 
2009; Mishra et al., 2013). Furthermore, depolarization of the distal axon reverses the action of 
the Na+/Ca2+ exchanger at the plasma membrane, which causes further intra-axonal calcium 
accumulation from extracellular sources (Stirling & Stys, 2010) (Figure 1).  
 Application of L-type VGCC inhibitors, such as dihydropyridines, delay axotomy 
induced axon degeneration both in vitro (Bramely et al., 2016; Gerdts et al., 2011) and in vivo 
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(George, Glass, & Griffin, 1995). This observation supports the important role of depolarization 
since dihydropyridines, such as nifedipine, block the voltage sensing of VGCCs, which is a 
necessary characteristic for activating channels on intra-axonal calcium stores such as the 




2.3 Calcium Dyshomeostasis 
2.3.1 Cytosolic calcium 
 Cytosolic calcium levels are kept very low (~100nM) during homeostasis. However, 
there is a substantial increase in intra-axonal calcium levels in response to injury. As mentioned 
previously, one proposed mechanism of this calcium rise is due to L-type voltage gated calcium 
channel activation. Upon VGGC activation, an influx of extracellular calcium into the axon is 
observed as well as activation of calcium release from intra-axonal stores, such as the 
axoplasmic reticulum (AR) and mitochondria (Villegas et al., 2014). Such large increases in 
calcium allow for calcium sensitive proteases, such as calpain, to activate and degrade axonal 
cytoskeletal components (Ma et al., 2013). Although there are mechanisms in place to counter 
small-scale increases of calcium concentration, such as calcium buffers (Schwaller, 2010), the 




substantial increases observed in axon degeneration may allow for a positive feedback 
mechanism of release from intra-axonal compartments. 
 There are also transporters at the plasma membrane that function to remove calcium from 
the cytosol. The two transporters considered in the model are the plasma membrane calcium 
ATPase (PMCA) and Na+/Ca2+ exchanger (NCX) (Figure 2).  The PMCA hydrolyzes ATP to 
pump cytosolic calcium into the extracellular space. Its activity is also modulated by calmodulin. 
Upon calmodulin binding calcium to form the calcium-calmodulin complex (binding affinity in 
the low micro molar range), the complex can interact with a binding site near the PMCA’s C-
terminal domain to increase the ATPase’s affinity for calcium and release autoinhibiton (Brini & 
Carafoli, 2003; Zhou et al., 2013). Furthermore, binding of calcium-calmodulin exposes sites for 
phosphorylation by protein kinase C (PKC) to upregulate the PMCA’s removal of cytosolic 
calcium (Wang et al., 1991; Strehler & Zacharias, 2001). Under homeostatic conditions where 
the Na+/K+ ATPase is functioning, the NCX harnesses the sodium electrochemical gradient to 
remove calcium from the cytosol with a 4:1 stoichiometry (Dong, Dunn & Lytton, 2002). 
However, in injury conditions, there is a reversal of NCX activity at the axonal plasma 
membrane causing an influx of extracellular calcium (LoPachin & Lehning, 1997). Overall, 
these two transporters significantly contribute to the removal of calcium from the cytosol under 
homeostatic conditions and maintain important roles in axonal injury (Brini & Carafoli, 2011; 






2.3.2 Role of axoplasmic reticulum in calcium dyshomeostasis 
 The axoplasmic reticulum (AR) is an important target of intra-axonal calcium release. 
Calcium release from this store is robustly mediated through the ryanodine receptor (RyR) and 
inositol triphosphate receptor (IP3R) (Stirling & Stys, 2010; Villegas et al., 2014). The 
axoplasmic reticulum also acts as a sink for excess cytosolic calcium. Through the activity of the 
smooth endoplasmic reticulum calcium ATPase (SERCA) pump, the AR takes up cytosolic 
calcium rapidly in an ATP dependent manner.  
 Ryanodine receptors are activated by the accumulation of intra-axonal calcium and other 
signaling molecules such as cyclic ADP-ribose (cADPR) (Guse, 1999). Calcium binding affinity 




is enhanced for the RyR in the presence of cyclic ADP-ribose (cADPR) (Higashida et al., 2007). 
IP3Rs become activated when bound to inositol triphosphate (IP3). IP3 is generated by the 
cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) by phospholipase C (PLC). The PLCβ 
isoform becomes activated through G-protein coupled receptor signaling, and PLCγ is regulated 
through phosphorylation by tyrosine kinases (Kim et al., 1999). However, the activation of other 
isoforms such as PLCδ1, which is ubiquitously expressed in neuronal cells, relies on binding free 
calcium (Kim et al., 1999). Although all PLC isozymes are activated by Ca2+ in vitro, PLCδ 
seems more sensitive to Ca2+ than the other isozymes. Furthermore, PLC activity is attenuated 
through activated PKC. An increase in Ca2+ ion concentration within the physiological range 
(0.1–10 μM) is sufficient to stimulate PLCδ1 but not PLCβ1 (Kim et al., 1999). For simplicity, 







2.3.3 Role of mitochondria in calcium dyshomeostasis 
 Mitochondria are also an important intracellular source of calcium. At small increases of 
cytosolic calcium, the mitochondria serve as a sink to buffer the fluctuation. However, larger 
perturbations in cytosolic calcium lead to mitochondrial dysfunction and release of its calcium 
(Brookes et al., 2004; Yan et al., 2006; Court, & Coleman, 2012). Following axonal injury, there 
is a loss of mitochondrial membrane potential and prominent mitochondrial swelling in distal 
axon segments before fragmentation (Park et al., 2013; Barrientos et al., 2011).  




 There is evidence that axoplasmic calcium release through ryanodine and IP3 receptor 
activity leads to the opening of the mitochondrial permeability transition pore (mPTP), which is 
a crucial event in axotomy induced axon degeneration (Villegas et al., 2014; Barrientos et al., 
2011). Cytosolic calcium enters the mitochondria through the mitochondrial uniporter (MCU), 
which may lead to calcium overload and subsequent opening of the mPTP (Chappell & Crofts, 
1965; Crompton & Costi, 1985; Villegas et al., 2014). Through the mPTP, calcium can exit the 
mitochondria and flood into the cytosol along with other mitochondrial solutes under 1.5kDa 
(Peng & Jou, 2010; Giacomello et al., 2007; Marchi et al., 2014). Other consequences of mPTP 
opening in axon degeneration include the loss of the mitochondrial membrane potential 
(Halestrap, 2009), decrease in ATP production (Villegas et al., 2014), and generation of reactive 
oxygen species (ROS) (Court & Coleman, 2012). Through loss of the membrane potential, 
calcium may also leave the mitochondria through the reversal of the MCU (Giacomello et al., 
2007). 
 The model also includes antiporters present on the mitochondrial membrane including the 
Na+/Ca2+, H+/Ca2+, and the Na+/H+ exchanger (Figure 4). The Na+/Ca2+ and H+/Ca2+ exchangers 
both extrude calcium from the mitochondria with a stoichiometry of three sodium or hydrogen 
ions for every two calcium ions (Giacomello et al., 2007), and the Na+/H+ exchanger shuttles one 
sodium ion out of the mitochondria while one hydrogen ion is removed from the cytosol. The 
transport of each species in this model is electroneutral and based off respective species’ 
concentration gradients. These antiporters maintain a substantial role in the movement of ions 















2.4 NAD Biosynthesis 
Nicotinamide adenine dinucleotide (NAD) biosynthesis is represented in the model 
through the NAD salvage pathway. Although the de novo pathway utilizing tryptophan also 
contributes to the generation of NAD, the salvage pathway is heavily relied on for NAD 
synthesis and is representative of the mechanism used by neurons in primary culture (Canto et 
al., 2015; Nikiforov et al., 2011). NR and Nam, collectively termed niacins, are precursors used 
in the NAD salvage pathway (Belenky, Bogan, & Brenner, 2007; Stein & Imai, 2012). NR is 
converted into nicotinamide mononucleotide by NRK and Nam is converted into NMN by 
nicotinamide phosphoribosyl transferase (NAMPT). Nam is the precursor of the salvage pathway 




considered in the model since it is the main substrate present in cell culture media (Nikiforov et 
al., 2011).  
2.4.1 NAMPT 
 As mentioned above, NAMPT converts Nam into NMN, which can then contribute to the 
cytosolic NAD pool (Figure 5). NAMPT is also homogeneously distributed in neurons (Esposito 
et al., 2012), and is the rate limiting enzyme of NAD synthesis from the salvage pathway. 
Although it is intuitive that inhibition of NAMPT decreases NAD synthesis, and studies have 
demonstrated elevated levels of NAD to be protective (Bramely et al., 2016; Sasaki et al., 2009; 
Shen et al., 2013), NAMPT inhibition actually protects against Wallerian degeneration. Studies 
inhibiting NAMPT activity usually employ the compound FK866 (Bramely et al., 2016; Sasaki 
et al., 2009; Shen et al., 2013; Esposito et al., 2012). Inhibiting NAMPT raises the concentration 







2.4.2 NMNAT enzymatic function and degradation by PHR1 
Nicotinamide mononucleotide adenylyl transferase (Nmnat) uses ATP to convert NMN 
into NAD (Figure 6). There are three isoforms: Nmnat1, Nmnat2, and Nmnat3. Each isoform is 
localized to a different compartment in neurons (DiStefano & Conforti, 2013; Lau et al., 2009). 
Nmnat1 is localized to the nucleus, Nmnat2 is found in the cytosol and undergoes anterograde 
transport in axons, and Nmnat3 is localized to the mitochondria (Berger et al., 2005). Nmnat1 is 
the protective subunit of the WLDs protein, and other studies expressing Nmnat demonstrate its 
protective effects against Wallerian degeneration (Araki et al., 2004; Babetto et al., 2010). 
Although Nmnat1 is normally expressed in the nucleus, its protective role in WLDs displays an 
extranuclear mechanism of protection (Coleman & Freeman, 2010; Beirowski et al., 2009; 
Yahata et al., 2009; Cohen et al., 2012). Furthermore, expression of Nmnat1 outside of the 
nucleus confers robust axonal protection (Sasaki et al., 2009; Sasaki & Milbrandt, 2010). Due to 
this protective cytosolic localization, high neuronal specific expression, and the necessary 
expression to prevent axon degeneration, the model considers Nmnat2 and its transport (Gilley & 
Coleman, 2010). Importantly, Nmnat2 loss is sufficient to induce Wallerian degeneration (Gilley 
et al., 2013; Hicks et al., 2012). Further studies correlating Nmnat2 turnover and onset of axon 
degeneration lend support for considering the Nmnat2 isoform (Gilley & Coleman, 2010; 
Beirowski et al., 2005; Yan et al., 2010). 
 The model also encompasses the ability of Nmnat to catalyze the reverse direction 
generating NMN and ATP from NAD. The directionality of the reaction is dependent on the 




relative concentrations of NAD and NMN, where the relative abundance of one will shift 
synthesis in favor of the other. 
 Nmnat maintains a short half-life, where its turnover rate is approximately 4 hours 
(Gilley & Coleman, 2010). This rapid turnover is due to its association to Golgi-derived vesicles 
through an intact palmitoylation site (Milde et al., 2013) during axonal transport and degradation 
by the ubiquitin-proteasome system, where degradation of Nmnat2 is directed by the E3 
ubiquitin ligase PHR1 (Gilley & Coleman, 2010; Babetto et al., 2013). The model also 
incorporates transport of Nmnat2, and the introduction of injury blocks this transport to the distal 
axon. The decrease in axonal Nmnat2 in response to axotomy is inversely correlated with the 




Figure 6 Enzymatic activity of Nmnat and degradation of 




2.4.3 NAD compartmentalization  
 There are distinctive pools of NAD in a cell: nuclear, cytosolic, and mitochondrial 
(Belenky, Bogan, & Brenner, 2007; Stein & Imai, 2012). The model considers cytosolic and 
mitochondrial NAD pools since after injury these are the only two pools available in the distal 
axon segment (Figure 7). Cytosolic NAD is synthesized from various extracellular precursors 
including NR, NA, NAR, and Nam. These precursors are derived from diet in living organisms. 
In cell culture, however, it is common for the only NAD precursor available to be Nam. Due to 
variability in diet and the majority of NAD being derived from Nam in physiological settings, the 
model only considers synthesis of cytosolic NAD from the Nam precursor (Nikiforov et al., 
2011).  The model also includes the cytosolic NADase SIRT2, which generates Nam through 
NAD cleavage, and the plasma membrane associated NADase CD38, which cleaves NAD to 
give Nam and ADPR or cADPR (Belenky, Bogan, & Brenner, 2007; Stein & Imai, 2012). 
 The mitochondria contain up to 70% of the cell’s NAD and cannot traverse the 
mitochondrial membrane (Nikiforov et al., 2011). Since Nmnat3 is found at very low levels in 
neurons, this enzyme’s presence in mitochondria allows for only small levels of mitochondrial 
NAD synthesis and is omitted from this mathematical model. The intermediate NMN in the 
NAD biosynthesis pathway has been shown to cross the mitochondrial inner membrane through 
an unidentified channel to serve as a precursor for mitochondrial NAD synthesis (Nikiforov et 
al., 2011). It is important to include this NAD pool in the model due to its significant size. 
Furthermore, opening of the mPTP in axon degeneration is a well-characterized event that allows 
all molecules of 1.5 kDa or less to exit the mitochondria into the cytosol including NAD. Thus, 












2.5 SARM1 and NAD consumption 
2.5.1 Generation of NAD cleavage products and influence on calcium release 
 Recently, the novel NADase activity of sterile alpha and TIR motif-containing protein 1 
(SARM1) was discovered (Essuman et al., 2017). The cleavage products from SARM1’s activity 
include ADP-ribose (ADPR), cyclic ADP-ribose (cADPR), and nicotinamide (Nam). Both 
ADPR and cADPR influence calcium concentration in the distal axon by regulating channels at 
the plasma membrane and internal membranes respectively (Perraud et al., 2001; Till and 
Ladurner, 2009; Guse et al., 1999). ADPR binds TRPM2 at the axonal plasma membrane 
(Sumoza-Toledo & Prenner, 2011; Islam, 2012), which contributes to the influx of extracellular 
calcium into the cytosol. TRPM2 also acts to cleave ADPR generating AMP (Sumoza-Toledo & 
Prenner, 2011). cADPR enhances calcium release from the axoplasmic reticulum through 
binding ryanodine type II receptors to increase their open probability as well as their affinity for 
calcium (Cancela et al., 2000; Higashida et al., 2007). cADPR can act as an agonist on ryanodine 
Figure 7 Cytosolic and mitochondrial NAD and contributions 




receptors to increase cytosolic calcium levels as well as act cooperatively with calcium to induce 
feed forward mechanisms of calcium release at ryanodine receptors (Higashida et al., 2001). 
Nam was also shown to provide negative feedback to NAD cleavage by SARM1 (Essuman et al., 
2017). The implications of SARM1’s action are of high interest in the context of Wallerian 
degeneration since there are precipitous drops in NAD after a lag phase (approximately 4 hours) 
immediately before observable degeneration in injured axons. However, the mechanism of this 
drastic drop along with NAD’s significance in the Wallerian degeneration remain elusive 
(Freeman, 2014). 
 In the model, SARM1 contributes to the consumption of NAD in response to axonal 
injury (Figure 8). A well-known class of NAD consuming enzyme includes ADP ribose cyclases, 
such as CD38. CD38 generates ADPR and cADPR and can hydrolyze cADPR to ADPR (Graeff 
et al., 2009; Belenky, Bogan, & Brenner, 2007; Higashida et al., 2007). This enzyme was 
included for its ubiquitous expression in neurons (Mizuguchi et al., 1995). However, CD38 
knockout models of axonal injury confer no protection against axon degeneration (Sasaki et al., 
2009), whereas expression of SARM1 is necessary for Wallerian degeneration to occur (Osterloh 
et al., 2012). 
 The model also investigates the temporal dependence of SARM1’s activation as well as 
its dependence on the presence of Nmnat2 as there are no identified activators of SARM1. 
SARM1 activation in the model is represented as the proposed “trophic factor model” (Freeman, 
2014), which states that the presence of a survival factor (Nmnat2) is needed to suppress the 
default axon destruction program (SARM1 activation and Wallerian degeneration). Although it 
remains unclear if the presence of Nmnat2 inhibits SARM1 enzymatic activity, whether through 
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direct or indirect mechanisms, the model inversely correlates the concentration of Nmnat2 with 




2.6 Energy Dyshomeostasis 
2.6.1 NAD depletion 
 In axon degeneration, precipitous drops in ATP and NAD are seen about 4 hours 
following axotomy. However, axons remain viable at about 30% of original ATP concentration 
(Shen et al., 2013). NAD is coupled to ATP production through the electron transport chain 
(ETC). To contribute to ATP production in the ETC, NAD must be in its reduced form, NADH 
(Figure 7). NADH is generated through glycolysis in the cytosol and uses the malate-aspartate 
shuttle to move its reductive capacity into the mitochondrial matrix. NAD that is in the 





mitochondrial matrix can also become reduced to NADH through the tricarboxylic acid (TCA) 
cycle. 
 The malate-aspartate shuttle consists of cytosolic malate dehydrogenase, mitochondrial 
malate dehydrogenase, malate-alpha-ketoglutarate antiporter, and glutamate-aspartate antiporter 
(Berg, Tymoczko, & Stryer, 2006). Cytosolic malate dehydrogenase oxidizes NADH and 
concurrently reduces oxaloacetate to malate. Malate is then able to enter the mitochondrial 
matrix via the malate-alpha-ketoglutarate antiporter. In the matrix, malate dehydrogenase 
oxidizes malate to oxaloacetate and reduces mitochondrial NAD to NADH. Oxaloacetate is 
transformed into aspartate by mitochondrial aspartate aminotransferase and is moved into the 
cytosol by the glutamate-aspartate antiporter where it is converted back into oxaloacetate. The 
model has transport of NADH from the cytosol contingent upon the abundance of malate 
dehydrogenase present in the cytosol. It is assumed that concentrations of malate and 
oxaloacetate remain unchanged over the degenerative time course. 
 In the model, generation of NADH from cytosolic NAD via the glycolytic process is 
assumed to occur at a fixed rate since the concentrations of glycolytic enzymes in the context of 
axon degeneration have not been shown to be perturbed. A similar assumption is made for the 
conversion of matrix NAD being reduced to NADH via the TCA cycle.  
 In the presence of NADH and FADH2, the ETC oxidizes these electron carriers and is 
able to move matrix hydrogen ions into the inter membrane space of the mitochondria. 
Generation of ATP is by the ATP synthase, which moves four hydrogen ions down hydrogen’s 
concentration gradient from the inter membrane space into the matrix and combines ADP and 
inorganic phosphate to form ATP. The model assumes there is an abundance of ADP and 
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inorganic phosphate, thus making generation of ATP by ATP Synthase dependent upon the 
proton gradient established by the ETC oxidizing available electron carriers (Figure 7).  
2.6.2 Influence of ATP depletion on cytosolic calcium  
 As mentioned previously, reductions in ATP lead to failure of the Na+/K+ ATPase and 
subsequent depolarization of the distal axon mediating extracellular influx via L-type VGCCs. 
Additionally, ATP reductions may contribute significantly to calcium accumulation from 
intracellular stores. The SERCA pump on the AR is a crucial ATPase for the reuptake of 
cytosolic calcium (stoichiometry of calcium to ATP is 2:1). At significantly decreased levels of 
ATP, failure of this pump may have a substantial contribution to the rapid accumulation of 
cytosolic calcium immediately preceding axonal fragmentation. Furthermore, under low ATP 
concentrations, failure of the PMCA (stoichiometry of calcium to ATP is 1:1) may also 
contribute to cytosolic calcium accumulation.  
2.7   Degeneration 
 Calpastatins, which inhibit calpains, effectively block the fragmentation observed in axon 
degeneration (Yang et al., 2013). Specifically, m-calpain is implicated in Wallerian degeneration 
(Ma et al., 2013). Thus, the model incorporates such calcium sensitive proteases, which become 
activated in the range of cytosolic calcium 100uM - 1000uM. Common cytoskeletal substrates 
cleaved by m-calpain and crucial to structural integrity of the axon including alpha tubulin, beta 
tubulin, and neurofilament heavy chain (NF-H), are represented in the model initially as intact 






2.8   Mathematical Modeling using Biochemical Systems Theory 
 The visual models shown and described above are represented mathematically according 
to Biochemical Systems Theory (BST). BST is a mathematical framework of ordinary 
differential equations (ODEs) utilizing power law expansions to represent biochemical pathways 
(Voit, 2000). Mathematical models using power law expansions have been used to represent and 
analyze various biochemical systems including metabolic and genetic networks as well as cell 
signaling pathways (Broome & Coleman, 2011; Braatz & Coleman, 2015). 
 In this work, MATLAB R2017b was used to analyze a system of nonlinear, first order, 
autonomous ordinary differential equations. (For full code, see Appendix). The two categories of 
ODEs used are termed system equations and rate equations. System equations (Equation (1)) 
demonstrate the change of a variables’ concentration over time depending on precursors, 
consumers, activators, and inhibitors of the variable. 





Equation (1)  
𝑑𝑋(2)
𝑑𝑡
= 𝑋(1) ∗ 𝑘𝑠𝑦𝑛𝑡ℎ𝑒𝑠𝑖𝑠 − 𝑋(2) ∗ 𝑘𝑑𝑒𝑔𝑟𝑎𝑑𝑎𝑡𝑖𝑜𝑛 
𝑋(1)
𝑘𝑠𝑦𝑛𝑡ℎ𝑒𝑠𝑖𝑠
→      𝑋(2)
𝑘𝑑𝑒𝑔𝑟𝑎𝑑𝑎𝑡𝑖𝑜𝑛
→         ∅ 
Here, the ODE shown represents the change in concentration of species 𝑋(2) over time. This example reaction has 
no modifiers. The rates of synthesis and degradation of 𝑋(2) are 𝑘𝑠𝑦𝑛𝑡ℎ𝑒𝑠𝑖𝑠 and 𝑘𝑑𝑒𝑔𝑟𝑎𝑑𝑎𝑡𝑖𝑜𝑛 respectively. 
If a reaction has modifiers, rate equations (Equation (2)) are used to describe the change 
in rate of catalysis or inhibition on a reaction over time corresponding to the prevalence of 
activators or inhibitors, respectively. The rate equation applying to a reaction consists of a 
constant multiplied by the sum of all activator and inhibitor species. In the sum, activators are 




= 𝐶 ∗ [𝑋(3) − 𝑋(4)] 
𝑋(1)
𝑋(5)
→  𝑋(2) 
Here, we consider the synthesis of 𝑋(2) to be dependent on the presence of catalyst 𝑋(3) and inhibitor 𝑋(4). Thus, 
the rate of synthesis is no longer represented as 𝑘𝑠𝑦𝑛𝑡ℎ𝑒𝑠𝑖𝑠, but as a new value 𝑋(5) that changes in time. 𝐶 is a 
constant that can be empirically determined for each reaction. 
 Each species in the model is assigned a concentration, and each reaction has a 
corresponding rate. These values were derived from databases (PaxDB, PBD, and HMDB) and 
primary literature. For proteins, values were obtained in parts per million from the frontal cortex, 
and through utilization of corresponding molecular weights, were converted to micro molar 
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concentration. Furthermore, each species is categorized as a dependent or independent variable. 
Dependent variables are defined as species that will change in concentration over time. 
Independent variables are defined as species that are not a product of a reaction in the model, and 
thus will maintain constant concentration over time. 
 The figures generated by the model fall into three categories: control condition (baseline), 
injured condition (axotomy), and treatment condition. To analyze the effect of treatments, the 
difference between the states were taken where applicable. By taking the difference between 
treatment and control conditions and difference between treatment and disease conditions 
respectively, we can qualitatively assess the effectiveness of treatments and their targets. Any 
positive values for species then indicates an increase between states, and negative values indicate 
decreases. For each treatment, there were two categories: early treatment and late treatment. 
Early treatment is administered at the beginning of the injury (t=0.1). 
3. Results 
The results encompass qualitative predictions for potential mechanisms of Wallerian 
degeneration. Such mechanisms were investigated through the introduction of pharmacological 
treatments frequently used on primary neuronal cultures and knockout conditions for certain 
species in the mathematical model. All pharmacological treatments were administered early in 
the program run time (t=0.1). Each alteration’s impact on the molecular events of the axon 






3.1 Characterization of Wallerian Degeneration in Zebra Finch RGCs 
   Equation (3)              





Degeneration Index (DI) is the fraction of degenerated axons where 0 represents no degeneration and 1 
represents complete degeneration. 
 
Equation (4)                








Where 𝑡50 is time of 50% degeneration (DI = 0.5), 𝑡 is total time of degeneration (DI = 1), and 𝐻𝑖𝑙𝑙 is the slope 
of the sigmoidal function. 𝑦 represents the normalized DI value. 
 
Retinal ganglion cells (RGCs) derived from zebra finch embryos were plated and subjected 
to mechanical injury to induce Wallerian degeneration (Figure 10a). Quantification of 
degeneration is described in Equation (3). Time-lapse imaging was used to generate a sigmoidal 
fit (Equation (4)) for the time course of degeneration (Figure 10b). Injured axons reached 
maximal degeneration by about 13 hours (Figure 10c).  
Axotomized axons were subjected to various dosages of nifedipine (3 µM, 6 µM, and 18 
µM) to block L-type VGCCs. Treatment of axotomized axons with 6 µM nifedipine 
demonstrated peak protectiveness (Figure 10d). This nifedipine treatment provided 42% 
protection compared to axotomized axons with no nifedipine treatment (Figure 10e). Solving for 
the corresponding 𝑡50 from Equation (4) and applying a logistical regression fitted curves for 
degeneration in the nifedipine treatments. Injured axons reached maximal degeneration by about 
23 hours when treated with 6 µM nifedipine (Figure 10c). 
3.2 Simulation of Axotomy 
Controls were first established before introduction of perturbations to the degenerative 
pathway. In the control condition, there is no axotomy and thus no perturbation to the system 
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components. Axotomy (axon transection) initiating the degenerative pathway induces the halt of 
Nmnat2 transport from the soma down the axon (Figure 11a).  
The activation of the central executioner protein, SARM1, is inversely correlated with the 
presence of Nmnat2 in the axotomy model (Figure 11a,b). Upon axotomy, there is a fast 
activation of SARM1 followed by a later decline mediated by Nam inhibition and an intrinsic 
inactivation rate (Figure 11b). Due to rapid SARM1 activation, there is an early decline in 
cytosolic NAD and corresponding early increase in ADPR and cADPR products (Fig 11c,d). The 
increases in these cleavage products occur in ratios of product to original NAD concentration 
comparable to ratios generated in studies characterizing the NADase activity of SARM1 
(Summers et al., 2016; Essuman et al., 2017).   
Calcium released from cADPR-activated RyR channels may be taken up by the mitochondria 
via the MCU causing an increase in matrix calcium (Deniaud et al., 2008; Villegas et al., 2014; 
Vargas et al., 2015). In the model, rises in matrix calcium are sufficient to open the mPTP. The 
early rise in cADPR observed in the axotomy model is sufficient to cause increases in matrix 
calcium for mPTP opening. Upon opening of the mPTP, mitochondrial species are lost to the 
cytosol, including NAD (Figure 11e). This new contribution of NAD to the cytosol provides 
active SARM1 a larger substrate pool to generate a larger, later increase in ADPR and cADPR. 
With this substantial increase in NAD cleavage products, many RyR channels become activated 
causing the start of substantial cytosolic calcium accumulation. Although cADPR is the minor 
product of NAD cleavage by SARM1, its cyclic structure makes cADPR very stable with a 
relatively long half-life on the time scale of days (Storey & Storey, 2002). In contrast, the 
presence of ADPR, a major product of SARM1 NADase activity, is transient with a half-life 
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commonly observed on the time scale of minutes under stress conditions (Storey & Storey, 2002; 
Hassa et al., 2006). Therefore, both molecules may substantially influence cytosolic calcium. 
Additionally, upon opening of the mPTP, the mitochondria lose their membrane potential, 
and thus their full capacity to generate ATP (Figure 11f). This energy failure in the distal axon 
causes depolarization and opening of the L-type VGCCs allowing for a steady influx of 
extracellular calcium into the cytosol. This event of VGCC opening is evident in the inflection 
point observed in cytosolic calcium (Figure 11g). Furthermore, large cytosolic calcium 
accumulation is promoted by energy failure through the inactivity of calcium ATPases and feed 
forward calcium release mechanisms from intracellular stores. 
In response to large, prolonged increases in cytosolic calcium, calcium sensitive proteases 
become activated. In the model, m-calpain is the calcium sensitive protease that becomes 
activated by 100-1000 µM cytosolic calcium concentrations observed during axotomy (Khorchid 
& Ikura, 2002). With calpain activation, there is an increase in degraded cytoskeletal products, 
which follows the characteristic sigmoidal function of degeneration (Figure 11h). In Figure 11h, 
the curve flattens once all cytoskeletal components are degraded at approximately t=62. 
3.3 SARM1 Knockout 
Representation of a knockout requires the removal of the variable from the axotomy model. 
Removing SARM1 from the model yielded cytosolic NAD levels in axotomy comparable to that 
of the control (no axotomy) (Figure 12a). With the preservation of NAD, there are high levels of 
ATP, which will prevent depolarization of the distal axon in the time span considered (Figure 
12b). There was also no generation of an early spike in cADPR that would cause cytosolic 
calcium uptake by the mitochondria, and thus no mPTP opening (Figure 12c). Furthermore, 
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cytosolic calcium in SARM1 knockout axotomy was similar to cytosolic calcium concentration 
of the control (Figure 12d). Since there was no calcium accumulation, there is no synchronized 
degeneration observed (Figure 12e). Any degeneration that occurs does so over a significantly 
longer time span compared to axotomy at basal calpain activity. 
3.4 Nmnat2 Knockout 
Removing Nmnat2 from the control model caused an increase in the amount of active 
SARM1 comparable to axotomy (Figure 13a). With similar amount and duration of active 
SARM1, there is a corresponding decrease in cytosolic NAD and increase in cleavage products 
(Figure 13b,c). Additionally, there is comparable cytosolic calcium accumulation to the axotomy 
model (Figure 13d). This calcium accumulation facilitates the opening of the mPTP, which in 
turn hinders ATP production by mitochondria. Chronic activity of calcium ATPases also 
contributes to the ATP decline observed, which feeds forward into further cytosolic calcium 
accumulation (Fig 13e). With similar time courses in ATP depletion and cytosolic calcium 
accumulation, the degeneration time course proceeds similarly in the Nmnat2 knockout of the 
control model compared to the axotomy model (Figure 13f). 
3.5 PHR1 Knockout 
Knockout of the ubiquitin proteasome PHR1 significantly increases the half-life of Nmnat2 
(Babetto et al., 2013). To test this in the model, PHR1 was removed from the axotomy condition. 
Removing PHR1 yielded a large increase of axonal Nmnat2 similar to levels in the control model 
(Figure 14a).  As a result of sustained Nmnat2 levels in the time course considered, SARM1 
remained inactivated (Figure 14b). Without SARM1’s enzymatic activity, there was no 
observable NAD cleavage, energy failure, or cytosolic calcium accumulation (Figure 14c-f). In 
33 
 
the absence of cytosolic calcium accumulation, there was only slow degeneration generated from 
basal activity of calpain in the model (Figure 14g). 
3.6 Nifedipine Treatment 
Treatment with nifedipine blocks L-type VGCCs. In primary neuronal culture, nifedipine 
treatment provides a short period of protection through delaying cytosolic calcium increases 
(Bramley et al., 2016; George, Glass, & Griffin, 1995). Nifedipine treatment in the model is set 
at 6 µM, which has been shown to be an effective dosage as previously presented in assays with 
zebra finch RGCs (see section 3.1).  
Axotomy in the nifedipine treatment condition activates SARM1 to the same levels and 
length of time as axotomy with no drug treatment (Figure 15a). Since nifedipine treatment also 
does not affect mPTP opening, comparable amounts of ADPR and cADPR are generated during 
nifedipine treatment axotomy condition and no treatment axotomy condition (Figure 15b). 
Therefore, RyR receptors on internal calcium stores are activated similarly and release 
comparable amounts of calcium, which is evident early on in calcium accumulation (Figure 
15c,d). 
Although the mPTP opening causes energy failure in no treatment axotomy as well as 
nifedipine treatment axotomy, nifedipine demonstrates slightly elevated ATP levels over time 
(Figure 15e).  This elevation in ATP may be attributed to the lower level of calcium ATPase 
activity in response to slower cytosolic calcium accumulation in nifedipine treatment axotomy. 
Slow cytosolic calcium accumulation is due to the inactivity of the VGCCs in spite of energy 
failure, leaving the main source of calcium accumulation to be released from internal stores. 
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Due to a slower time course of cytosolic calcium accumulation in nifedipine treatment, it 
takes longer for the cytosolic concentration to reach the high micromolar range where calpains 
are activated. Thus, the delayed calpain activation causes a delay in the axonal degeneration time 
course. However, when calpains become activated degeneration proceeds at a rate comparable to 
no treatment-axotomy (Figure 15f). 
3.7 FK866 Treatment 
FK866 treatment inhibits the action of NAMPT from converting Nam to NMN. In primary 
neuronal culture, FK866 treatment provides modest protection, although the protective 
mechanism remains elusive (Conforti, Gilley, & Coleman, 2014). FK866 treatment in the model 
is set at 0.5 µM, which has been shown to be in the range of effective dosage from previous 
assays with zebra finch RGCs (Bramley et al., 2016). Differences between species were obtained 
through the difference of the FK866 treated-axotomy and no treatment-axotomy models. 
In response to FK866 treatment there is a slight decrease in the amount of active SARM1 
compared to axotomy with no treatment (Figure 16a). The model represents an inhibiting effect 
of Nam binding SARM1 since Nam is an inhibiting cleavage product of SARM1 (Summers et 
al., 2016; Essuman et al., 2017). Support for the mechanism of FK866 treatment is observed in 
the substantial increase of Nam (Figure 16b). 
With a decreased amount of active SARM1 due to increased Nam levels, there is a net 
decrease in formation of NAD cleavage products (Figure 16c). In response to injury, SARM1 in 
FK866 treatment-axotomy has slightly lower initial activation levels, which decreases cADPR 
production and slightly attenuates rises in initial cytosolic calcium delaying mPTP opening. With 
delayed release of NAD from the mitochondria via the mPTP (Figure 16d), the time course of 
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ADPR and cADPR generation by SARM1 will also be delayed along with the effects of these 
products of cytosolic calcium accumulation. 
However, in addition to forming ADPR and cADPR upon cleavage of NAD, SARM1 forms 
Nam (Summers et al., 2016; Essuman et al., 2017). Around the time of peak cytosolic NAD, due 
to release from the mitochondria, there is a rapid decline in the amount of active SARM1. With 
FK866 treatment-axotomy, active SARM1 decrease is more dramatic than no treatment-
axotomy. This more pronounced decrease causes a net lower production of ADPR and cADPR 
of the second spike in Fk866 treatment (Figure 16c). With less cADPR and ADPR being formed, 
there are fewer active RyR and TRPM2 channels moving calcium present in the AR and 
extracellular space to the cytosol and thus slowing the rate of calcium accumulation (Figure 16f). 
Slower cytosolic calcium accumulation over time mediated through cADPR activated RyR 
receptors and ADPR activated TRPM2 receptors allows for less ATP consumption by calcium 
ATPases. With less ATP being consumed in FK866 treatment axotomy, which still experiences 
energy failure, it provides an increase in ATP at each time point compared to axotomy with no 
treatment (Figure 16f). With a small buffer in ATP availability, it will take longer for the axon to 
depolarize and activate VGCCs, thus contributing to a slower cytosolic calcium accumulation 
time course. 
As seen previously, slower cytosolic calcium accumulation in FK866 treatment due to 
decreased active SARM1 causes slower calpain activation and a subsequent delay in the axonal 
degeneration time course (Figure 16g). Thus, the protective action of FK866 treatment may be 




3.8 mPTP Inhibition 
Opening of the mPTP is an early event in axon degeneration since inhibition of the mPTP 
delays the onset of degeneration (Barrientos et al., 2011). To further explore the role of the 
mPTP in the degenerative pathway, inhibition was represented through the removal of the mPTP 
in the axotomy model.  
Inhibition of the mPTP prevents the loss of the mitochondrial membrane potential and loss of 
NAD to the cytosol (Figure 17a-c). Maintaining potential allows the mitochondria to preserve 
their ATP producing capacity thereby providing ATP for calcium ATPase activity and 
preventing depolarization of the distal axon in the time course considered. Without the 
contribution of mitochondrial NAD, the only rises in ADPR and cADPR are from SARM1 
cleaving cytosolic NAD, and no later rise in these products is observed (Figure 17c). These 
activities prevent large extracellular calcium influx and promote the removal of calcium from the 
cytosol. The early rise in calcium observed can be attributed to the activity of SARM1 (Fig 
17d,e). Since Nmnat2 is lost during axotomy, SARM1 activation is still apparent. However, there 
is a sustained level of active SARM1 since there is less cytosolic NAD substrate available 
resulting in less Nam production.  
Interestingly, despite a rise in cytosolic calcium, inhibition of the mPTP allows for the 
recovery of calcium concentration to more manageable levels in the time course considered. This 
recovery suggests that the release of NAD from the mitochondrial matrix provides an important 
substrate pool for SARM1 in the cytosol to generate the late rise in ADPR and cADPR, which 
enhance the movement of calcium from the extracellular space and intracellular stores 
respectively. This also suggests that early SARM1 activity causes a rise in mitochondrial calcium 
from cytosolic uptake to open the mPTP (Figure 17g). Furthermore, opening of the VGCCs and 
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their significant contribution to cytosolic calcium accumulation is prevented through the 
maintenance of energy homeostasis in mPTP inhibition during the time course. 
Although inhibition of the mPTP does suggest a crucial role in degeneration, it is not 
completely protective. Degeneration still proceeds, albeit on a slower time course, due to 
moderate activation of calpain through SARM1 activity (Figure 17f). 
Although the model considers a lower threshold for mitochondrial calcium concentration for 
mPTP opening than used in assays of mitochondrial swelling (Brustovetsky et al., 2003; 
Baumgartner et al., 2009; Wong, Steenbergen, & Murphy, 2013), this assumption is relevant since 
mitochondria take up calcium earlier in the lag phase before cytosolic calcium increases (Vargas 
et al., 2015), and the establishment of mPTP opening early on in the pathway may imply 
significant contributions to energy failure and VGCC activation. In general, oxidative stress 
maintains a significant role in mitochondrial dysfunction, and makes mitochondria more 
sensitive to calcium rises in formation of the mPTP (McStay, Clarke, & Halestrap, 2002). This is 
an important interaction to acknowledge since oxidative stress maintains an early role in axon 
degeneration (Press & Milbrandt, 2008; Fukui, 2016). 








Here, a general form of the reaction-diffusion equation is given for concentration of species A. 𝐷 represents the 
diffusion coefficient for A, and 𝐹(𝐴) represents the relevant reactions generating and consuming the species. 
 A reaction-diffusion model is used here to investigate the stochastic process of calcium 
diffusion in axon degeneration. The two species considered are cytosolic calcium and calpain. 
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The space considered (axon unit) is 10 µm in length with calcium release at t=0 occurring from 
only intracellular stores in the center (x=5 µm) and diffusing throughout the compartment over 
time. Calpain is assumed to be spread homogenously throughout the space, and calcium release 
occurs at one site in the axon unit. No flux boundary conditions were employed for the axon unit.  
The generation of active calpain occurs in the presence of cytosolic calcium 
concentrations greater than 100 µM. In the reaction-diffusion equations (Equation (5); see 
Appendix for the reaction-diffusion script), the formation of active calpain through inactive 
calpain binding free calcium (Kd = 25 µM) decreases the amount of free calcium and inactive 
calpain. The diffusion coefficient for calcium used in this stochastic model is two-orders of 
magnitude slower than the diffusion coefficient for freely diffusing calcium (D = 530 µm2/s) 
(Donahue & Abercrombie, 1987). This assumption is made due to the small diameter of RGC 
axons (0.2 – 3.6 µm), which creates a significantly smaller space for calcium diffusion 
(Drenhaus, von Guten, & Rager, 1997; FitzGibbon & Taylor, 2012). Smaller spaces are more 
conducive to molecular crowding and facilitate frequent molecular interactions between calcium 
and other calcium binding proteins, both of which are expected to slow the apparent diffusion 
coefficient for calcium.  
In cytoplasmic spaces of rod cells, with diameter on the same order as that of RGC axons, 
it has been shown that the diffusion coefficient for calcium may be 10 to 100 times slower than 
that of the free diffusion coefficient due to reversible binding interactions (McLaughlin & 
Brown, 1981). This slower diffusion coefficient is obtained from the established relationship 
when a species is simultaneously diffusing and partaking in reversible binding reactions. The 
diffusion coefficient is modified in the diffusion equation to be the apparent diffusion coefficient 
divided by 1 + 𝑅, where 𝑅 is the ratio of bound to free concentrations of the diffusing species 
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(Crank, 1956, p.347). As shown in rod cells, it is reasonable to assume there are 10 to 100 times 
as many calcium ions reversibly bound to other molecules as there are free calcium ions 
diffusing in the cytoplasm (McLaughlin & Brown, 1981). Experimental measurements of 
fluorescent calcium diffusion down the axons of rod cells, with comparable diameters to those of 
RGC axons, further support slower diffusion coefficients for calcium (Chen, Van Hook, & 
Thoreson, 2015). Due to molecular crowding shown in studies of fluorescent protein diffusion, 
these slower orders of magnitude in the diffusion coefficient of calcium have also been taken 
into consideration in other calcium reaction-diffusion models (Dayel, Hom, & Verkman, 1999; 
Means et al., 2006). Furthermore, estimations of calcium spread in dendrites have shown 
sensitivity to the presence of fixed calcium buffers and calcium spread of 5 µm or less from the 
site of release (Biess, Korkotian, & Holcman, 2011). 
 The initial conditions of this reaction-diffusion model define a homogenous distribution 
of inactive calpain in the axon and a local release of calcium following a Gaussian distribution 
that undergoes stochastic diffusion in the axon segments considered (Figure 18a,b). Therefore, it 
becomes evident that the distribution of active calpain is dependent on the location of calcium 
release, and degradation will occur locally (Figure 18c,d). Such behavior aligns with the 
characteristics of Wallerian degeneration in living systems and gives support to the trophic factor 
model. The trophic factor model states that the loss of a survival factor signals the start of the 
degeneration pathway. The reaction-diffusion model supports the trophic factor model since the 
loss of a survival molecule would initiate a series of events at the site of loss to cause a local 
release of calcium and thus local degradation (Lubinska, 1977).  
The trophic factor that is lost has been speculated to be Nmnat2 since its half-life aligns with 
the characteristic lag phase observed in degeneration, and removal of Nmnat2 is sufficient to 
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induce Wallerian degeneration in uninjured axons (Gilley & Coleman, 2010). If Nmnat2 is the 
crucial survival factor, one protective mechanism may be to inhibit SARM1 through direct or 
indirect mechanisms. This mechanism is supported by the prediction from the axotomy model 
that enzymatic activity of SARM1 facilitates calcium release, especially from intracellular stores, 
to promote calpain activation and subsequent degeneration. Thus, with SARM1 activity 
influencing the release of calcium from local stores, calpain activation and degeneration will 
occur in a spatiotemporal sequence following SARM1 activation. Furthermore, 90% of calcium 
release at the end of the lag phase in vivo originates at the site of injury or distal tips, which are 
locations where Nmnat2 would be lost earliest (Vargas et al., 2015). These locations of calcium 
release along with the predictions from the axotomy and reaction-diffusion models indicate that 
the spatiotemporal activation of SARM1 mirrors that of Nmnat2 loss, thus supporting a potential 
protective role of Nmnat2 through mediating SARM1 inhibition. 
Moreover, this reaction-diffusion model gives support to the initial generation of calcium 
mobilizing products, from cleavage of cytosolic NAD by SARM1, to be a significant contributor 
to mPTP opening through mitochondrial calcium overload. The axoplasmic reticulum (AR) and 
mitochondria are in close proximity (on the order of nm), which indicates possible calcium 
communication between the two stores (Villegas et al., 2014). The initial rise in cADPR 
generated from SARM1 activity in the axotomy model is sufficient to cause mitochondrial 
calcium overload and subsequent mPTP opening (Figure 11d). To further test the plausibility of 
this prediction, the reaction-diffusion equation for calcium encompasses an estimate of 100 µM 
release of calcium from the AR, due to stimulation of cADPR from initial SARM1 NADase 
activity, diffusing throughout the axonal unit (Fulceri et al., 2001; Chini et al., 2005; Essuman et 
al., 2017). Over a short period of time, relatively high levels of cytosolic calcium diffuse on the 
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order of 1 µm from the initial site of release (AR) (Figure 18e,f). This diffusion distance would 
readily encompass the close proximity of mitochondria to the AR, and expose the mitochondria 
to these high levels of cytosolic calcium for mPTP opening (Deniaud et al., 2008; Villegas et al., 
2014). Importantly, these levels of cytosolic calcium do not meet the threshold for m-calpain 
activation, which further supports mitochondrial calcium overload caused by calcium release 
from cADPR-activated RyRs and subsequent mPTP opening occur in the lag phase immediately 
preceding fragmentation. 
4. Discussion 
4.1 Axotomy: Qualitative similarities to degeneration in primary neuron culture 
The axotomy model qualitatively matches degenerative progression observed in    
living systems 
Injury causes the loss of Nmnat2 and, in the axotomy model, subsequent activation of 
SARM1. Initial SARM1 activity cleaves cytosolic NAD leading to rises in ADPR and cADPR 
and slow accumulation of cytosolic calcium. This cytosolic calcium accumulation and its 
proximity to mitochondria may induce mitochondrial calcium overload to trigger the opening of 
the mPTP, which impairs ATP production and causes the release of matrix NAD into the cytosol 
for further cleavage by SARM1. This NAD release correlates with a second, larger rise in ADPR 
and cADPR, which would have a stronger influence on calcium influx via TRPM2 receptors and 
release from intracellular stores via ryanodine receptors (RyRs). Although the production of 
cADPR is significantly less than that of ADPR, the half-life of cADPR is much longer compared 
to the transient presence of ADPR. This long half-life of cADPR suggests a longer stimulation of 
calcium release from the AR through activation of ryanodine receptors. From these predictions, 
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SARM1’s activity influencing cytosolic calcium accumulation should be verified in living 
systems. 
Furthermore, mPTP opening leads to energy failure and subsequent depolarization of the 
distal axon, which causes the opening of VGCCs to mediate the influx of extracellular calcium 
into the cytosol. 
The series of events from the model including early Nmnat2 loss, SARM1 activation, 
extracellular calcium influx through VGCCs, and degeneration following a sigmoidal function, 
qualitatively agree with the events of degeneration in vitro and in vivo (Barrientos et al., 2011; 
Park et al. 2013; Villegas et al., 2014 Vargas et al., 2015; Bramley et al., 2016). Importantly, the 
model suggests influential roles of SARM1’s novel NADase activity and mPTP involvement in 
energy failure and cytosolic calcium accumulation. 
4.2 Important protection mediated by Nmnat2 
The model activates SARM1 based on the presence of Nmnat2. Through treatments 
eliminating Nmnat2 or stabilizing this protein’s concentration over time, SARM1 activity is 
strongly modulated along with the degenerative time course in the model. Although there is no 
current data directly supporting this relationship, local action of proteins, such as calpain and 
SARM1, as well as anterograde and local axon degeneration support the need for testing this 
mechanism. 
First, the loss of Nmnat2 occurs early in the pathway due to Nmnat2’s short half-life. 
However, other than being active upstream of calpain activation, the role of SARM1 in the 
initiation or execution phases has been unestablished (Yang et al., 2013; Conforti, Gilley, & 
Coleman, 2014). The representation of SARM1 activation in the model, as no known activators 
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of SARM1 have been identified, proposes a mechanism where SARM1 is involved in the 
initiation phase of axon degeneration. Furthermore, over expression of SARM1 does not induce 
degeneration, thus indicating this protein needs an activating signal, which may be generated 
through Nmnat2 loss and remains to be tested in living cells and organisms (Gerdts et al., 2013). 
The incorporation of this correlation in the model between early Nmnat2 loss and SARM1 
activation gives a qualitatively similar progression of axon degeneration to that observed in vitro 
and is the first known study investigating this possibility.  
There is a hypothesis termed the trophic factor model suggesting that a continual supply of 
an unidentified trophic factor from the cell body suppresses the endogenously active 
degeneration pathway, which proceeds in the absence of this trophic factor (Lubinska 1977; 
Coleman & Freeman, 2010). Nmnat2 has been proposed to be this trophic factor since the lag 
phase observed after axonal injury would correlate with that of the half-life of the trophic factor. 
Indeed, the half-life of Nmnat2 is about 4 hours, which corresponds with the lag phase duration 
(Gilley & Coleman, 2010). Nmnat2 also relies on anterograde transport mechanisms to be 
transported from the cell body (site of production) to where it is needed further along the axon. 
Knocking down Nmnat2 is sufficient to induce Wallerian degeneration (Gilley & Coleman, 
2010). Furthermore, the protective protein WLDs has a longer Nmnat half-life compared to 
Nmnat2 (Gilley & Coleman, 2010). The stochastic reaction-diffusion model of calcium released 
from intracellular stores provides further support for the trophic factor model and implicates 
early SARM1 activation and mitochondrial dysfunction. With a possible early activation of 
SARM1 due to its novel NADase activity, Nmnat2 may be involved in mechanisms maintaining 
the inhibition of this enzyme. 
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Moreover, the enzymatic activity of proteases and SARM1 are confined locally to cause local 
axon degeneration (Gerdts et al., 2015). Thus, the loss of trophic factor from sites in the axon 
through anterograde axonal transport following injury would initiate degeneration with a 
corresponding anterograde directionality, which is observed in axotomized axons (Lubinska, 
1977; Beirowski et al., 2005). As demonstrated through the model of stochastic diffusion of 
calcium and calpain activation, the site of calcium release will dictate the site of highest active 
calpain concentration. Locations with active calpain undergo local degeneration. Furthermore, 
where there is activation of SARM1, the axotomy model predicts there is a subsequent 
accumulation of cytosolic calcium, which implies SARM1 activation occurs earliest at locations 
closest to the site of injury. Thus, loss of Nmnat2 through anterograde transport fits this 
characteristic of local activity of SARM1 and its influence on the progression of degeneration. 
Furthermore, research suggests that the NAD synthesis function of Nmnat2 is not necessary 
for protection against axon degeneration (Wang et al., 2005; Sasaki, Araki, & Milbrandt, 2006; 
Wang & He, 2009; Conforti, Gilley, & Coleman, 2014). Over expression of Nmnat2 or WLDs 
expression does not increase NAD levels compared to controls. Therefore, other substrates and 
products of Nmnat need to be considered since NAD does not confer protection in degeneration 
(Berbusse et al., 2016). A speculated protective product of Nmnat is increasing NAD availability 
for conversion into NADPH to act as a cofactor for ROS scavenging enzymes (Press & 
Milbrandt, 2008). Increasing NADPH may be beneficial in Wallerian degeneration to ameliorate 
the over production of ROS and attenuate the potential signaling roles of ROS in the pathway. 
Further research in primary cultures and animal models should focus efforts on identifying the 
protective role of Nmnat2, especially if there are direct or indirect influences on SARM1 
activity. Moreover, at the rate Nmnat2 produces NAD and consumes ATP, this enzyme working 
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in the reverse direction does not seem promising as its protective mechanism. The observation 
that NAD and ATP levels are very similar to that of uninjured axons in overexpression of 
Nmnat2 (to compensate for its short half-life) and WLDs (stable Nmnat that functions in the 
cytosol) may suggest SARM1 never becomes substantially activated to progress the degenerative 
pathway. 
4.3 Nifedipine and FK866 provide similar protection through convergence onto 
cytosolic calcium accumulation 
The protection conferred by nifedipine treatment in the axotomy model was qualitatively 
similar to that observed in vitro: nifedipine provided modest, but not complete protection. 
Furthermore, both systems show the hill (slope of the sigmoidal curve) of each nifedipine 
treatment degenerative function to be extremely similar to the respective axotomy treatment. 
This similarity may be due to cytosolic calcium concentration surpassing the threshold for m-
calpain activation and calpain activation occurring at the same approximate rates once the 
threshold is reached giving similar sigmoidal degeneration functions. Thus, the slow 
accumulation of cytosolic calcium initially in nifedipine treatment may be responsible for the 
observed delay between the two curves.  
After this slow accumulation, the second ADPR and cADPR spikes generated from SARM1 
activity and mPTP opening seem to be an important mechanism for mediating calcium release to 
reach cytosolic calcium levels that activate m-calpain. Although nifedipine treatment blocks the 
L-type VGCCs, it does not prevent Nmnat2 loss, subsequent SARM1 activation, mitochondrial 
calcium accumulation and mPTP opening. Without this second spikes in ADPR and cADPR 
from mPTP opening and active SARM1, there would be no activator in moving extracellular or 
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intracellular stores of calcium due to blockage of the L-type VGCCs, and thus no activation of 
m-calpains or local axon degeneration. 
FK866 treatment in the axotomy model is also qualitatively similar to this treatment in vitro 
by affording modest protection against degeneration. Until now, the mechanisms of FK866 
protection were unknown. Here, the protective mechanism mediated by FK866 treatment may be 
due to its facilitation of increasing levels of Nam, which is a negative feedback product of 
SARM1 activity (Essuman et al., 2017). In response to FK866 treatment, the model predicts that 
there is a rise in Nam, and corresponding decrease in active SARM1. However, the rise in Nam 
does not appear to be large enough to significantly decrease SARM1 activity to confer robust 
protective effects. Thus, the first spikes in ADPR and cADPR still occur, although these rises are 
delayed and dampened compared to those observed in the axotomy model. With these spikes still 
apparent, mitochondrial calcium accumulation may occur allowing for mPTP opening. 
Furthermore, Nam has an IC50 of 43.8 µM for SARM1 (Summers et al., 2016; Essuman et al., 
2017), whereas in the model the increase of Nam was about 12 µM. These relative 
concentrations support the result that the amount of active SARM1 is reduced, but not 
significantly enough to prevent degeneration from proceeding, albeit at a slower time course, in 
the mathematical model. 
Additionally, due to the delayed and slightly lower initial rises of ADPR and cADPR, the 
model predicts that FK866 treatment delays the second spikes of ADPR and cADPR. Since 
SARM1 inactivation in FK866 treatment is more pronounced than the axotomy only condition, 
the second spikes are also not as large, thus implicating slower cytosolic calcium accumulation 





4.4 SARM1’s novel NADase activity may involve the mPTP leading to energy failure 
and cytosolic calcium accumulation 
The model emphasizes the importance of SARM1’s novel NADase activity in propagating 
the axon degeneration pathway. Specifically, the first spikes in ADPR and cADPR suggests an 
important role in mPTP opening, and the second spikes provide a substantial contribution to 
cytosolic calcium accumulation.  
Due to the proximity of the mitochondria to sites of high calcium concentration near plasma 
membrane calcium permeable channels and the AR, mitochondria are clearly sensitive organelles 
to cytosolic calcium and are a sink for this calcium (Tsukita & Ishikawa, 1976; Villegas et al., 
2014). Furthermore, RyR activity can trigger axonal degeneration, but with mPTP inhibition, this 
degeneration is prevented. This mechanism of protection emphasizes calcium release from 
internal stores as a critical regulator of mitochondrial dysfunction by mPTP opening and 
supports the findings from the mathematical model (Park et al., 2013; Summers et al., 2014; 
Villegas et al., 2014). Therefore, it is a possible mechanism for initial generation of ADPR and 
cADPR (calcium movement via TRPM2 and RyRs respectively) by SARM1 to cause rises in 
cytosolic calcium sufficient to cause mitochondrial calcium overload.  
In the axotomy model, this mitochondrial calcium threshold is set lower than reported 
physiological levels that trigger mPTP opening (Halestrap, Woodfield, & Conneran, 1997; 
Halestrap, 2009;). However, this lowered threshold may be reasonable in the case of Wallerian 
degeneration since oxidative stress lowers the threshold for mitochondrial calcium in mPTP 
formation (McStay, Clarke, & Halestrap, 2002; Bernardi, 2013). Although the source(s) remain 
elusive, there is an early rise in ROS production following axonal injury (Milbrandt & Press, 
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2008; Fang, Bourdette, & Banker, 2012; Conforti, Gilley, & Coleman, 2014). Increases in 
mitochondrial calcium as well as mPTP opening may also contribute to an up regulation of ROS 
production leading to a positive feedback mechanism (Murphy, 2009; Peng & Jou, 2010; Court 
& Coleman, 2012). Therefore, mechanisms of ROS generation and relationship between ROS 
and the mitochondrial dysfunction via mPTP activity in Wallerian degeneration should be more 
thoroughly investigated. 
Moreover, mPTP opening is an important event in Wallerian degeneration (Barrientos et al., 
2011). Mitochondrial swelling, an indicative feature of mPTP opening, is apparent in axons up to 
12 hours before axon fragmentation, suggesting early involvement and a potential convergence 
point in the pathway (Barrientos et al., 2011). Furthermore, in living systems (Barrientos et al., 
2011) and this model, inhibition of the mPTP provides relatively robust protection against axon 
degeneration compared to nifedipine and FK866 treatments. mPTP activation in axons 
expressing WLDs can also cause axon degeneration, which suggests the protective mechanisms 
of WLDs and Nmnat lie upstream of mPTP opening and support mechanisms predicted by the 
axotomy model (Barrientos et al., 2011). Removal of mPTP formation confers protection 
observed in the model due to the preservation of energy homeostasis for the time period 
considered as well as the prevention of increased NAD substrate for cleavage by SARM1, which 
may suggest such protective mechanisms in living cells. This novel role for the mPTP predicted 
by the model should be verified in cell culture and animal models.  
This novel role for the mPTP in Wallerian degeneration is critical support for not only loss of 
the mitochondrial membrane potential, which has been speculated (Milbrandt & Press, 2008; 
Barrientos et al., 2011), but for the release of matrix NAD into the cytosol. Release of this NAD 
provides more substrate for cleavage by SARM1, which corresponds to the second spikes in 
49 
 
ADPR and cADPR generation. These later spikes, as predicted by the model, seem to be crucial 
in axon degeneration following its characteristic sigmoidal progression.  
Furthermore, studies on SARM1 localization support this mechanism of cytosolic NAD 
cleavage (Gerdts et al., 2013). SARM1 localizes to the mitochondria, but mostly resides on the 
cytosolic surface of the mitochondria. Moreover, deletion of SARM1’s mitochondrial 
localization signal does not prevent degeneration (Gerdts et al., 2013), which suggests its 
enzymatic NADase action in response to injury takes place in the cytosol. However, the majority 
of the cell’s NAD is stored in the mitochondria (Tischler et al., 1977; Stein & Imai, 2012). 
Therefore, through mPTP opening, release of matrix NAD may provide crucial substrate for the 
influence of SARM1 activity in Wallerian degeneration. Predictions of the model support this 
proposed mechanism since the prevention of mitochondrial NAD release strongly delays the 
degeneration time course. Therefore, this mechanism of mPTP opening and cytosolic NAD 
cleavage promoting a characteristic degeneration time course should be verified in living 
systems. 
5. Conclusion 
The aim of this mathematical model is to predict potential mechanisms of Wallerian 
degeneration to efficiently direct investigation in in vitro and in vivo systems. The results of this 
study predict SARM1’s NADase activity to maintain significant influence in Wallerian 
degeneration and support the two main hypotheses of this investigation. The initial hypothesis 
supported is SARM1’s cleavage products, namely ADPR and cADPR, may serve a significant 
contribution to cytosolic calcium accumulation through the movement of calcium from the 
extracellular space via calcium permeable membrane channels and from intracellular stores via 
RyRs. The second hypothesis is supported by the predicted involvement of early mPTP opening 
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due to SARM1’s NADase activity implicating the role of SARM1 in the characteristic energy 
failure observed in Wallerian degeneration. Such predictions should be verified in living systems 
to enhance understanding of the biochemical pathways mediating Wallerian degeneration and to 
generate novel therapeutic targets for degenerative conditions. 
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Abbreviations: 
Cyt Ca: Cytosolic Calcium  
Ext Ca: Extracellular Calcium  
Mt Ca: Mitochondrial Calcium  
AR Ca: Axoplasmic Reticulum Calcium  
Cyt Na: Cytosolic Sodium  
Ext Na: Extracellular Sodium  
Mt Na: Mitochondrial Sodium  
K: Potassium  
ATP: Adenosine Tri-Phosphate  
Pi: Inorganic Phosphate  
ADP: Adenosine Di-Phosphate  
VGCC: Voltage Gated Calcium Channel  
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NCX1: Sodium Calcium Exchanger 1  
CaM: Calmodulin  
CaM*: Active Calmodulin  
PMCA: Plasma Membrane Calcium ATPase  
PMCA*: Active Plasma Membrane Calcium ATPase  
PKC: Protein Kinase C  
PKC*: Active Protein Kinase C  
PLC: Phospholipase C  
PLC*: Active Phospholipase C  
PIP2: Phosphatidylinositol 4,5-bisphosphate  
IP3: Inositol Tri-phosphate  
IP3R: Inositol Tri-phosphate Receptor  
IP3R*: Active Inositol Tri-phosphate Receptor  
RyR2: Ryanodine Receptor 2  
RyR2*: Active Ryanodine Receptor 2  
SERCA: Smooth Endoplasmic Reticulum Calcium ATPase  
AR: Axoplasmic Reticulum  
cADPR: Cyclic ADP-ribose  
IMS H: Intermembrane Space Hydrogen  
Matrix H: Mitochondrial Matrix Hydrogen  
Cyt H: Cytosolic Hydrogen  
NAD: Nicotinamaide Adenine Dinucleotide  
NADcyt: Cytosolic NAD  
NADmt: Mitochondrial NAD  
MCU: Mitochondrial Uniporter  
mPTP: Mitochondrial Permeability Transition Pore  
mPTP*: Active Mitochondrial Permeability Transition Pore  
Nam: Nicotinamide  
Nam Ext: Extracellular Nam  
NAMPT: Nicotinamide Phosphoribosyltransferase  
NMN: Nicotinamide Mononucleotide  
NMNAT2 axon: Axonal Nicotinamide Nucleotide Adenylyltransferase 2  
NMNAT2 soma: Soma Nicotinamide Nucleotide Adenylyltransferase 2  
SARM1: Sterile Alpha And TIR Motif Containing 1  
SARM1*: Active Sterile Alpha and TIR Motif Containing 1  
PHR1: Phr1 E3 ubiquitin ligase  
CI: Complex I of the electron transport chain  
CIII: Complex III of the electron transport chain  
CIV: Complex IV of the electron transport chain  
TCA: Tricarboxylic Acid Cycle  
ADPR: ADP-ribose  
CD38: Cyclic ADP Ribose Hydrolase  
Sirt2: Sirtuin 2  
TRPM_2: Transient Receptor Potential Cation Channel Subfamily M Member 2  
TRPM2*: Active Transient Receptor Potential Cation Channel Subfamily M Member 2  
Cleaved Cytsk: Cleaved Cytoskeletal Components 
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Figure 10a Axons 15 hours post-axotomy of a RGC explant. Red dashes indicate the 
site of injury. 
Figure 10b Time lapse of degeneration showing zoomed section of distal 
axons to injury site at 1.5 hours, 5.5 hours, and 10.5 hours. 
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Figure 10c Degeneration time course of distal axons following axotomy with and without 
nifedipine treatment. Dashed lines represent 
+
−
 SEM of t50 (SEM~5.4%); Nifedipine (Nif). 





   
Figure 10e Percent degeneration of distal axons following 
axotomy at 15 hours. * Indicates p<0.05, ** p<0.01 
Figure 11a Presence of Nmnat2 in control and axotomy models. 






Figure 11b Presence of Active SARM1 in axotomy and control models. In the axotomy 
model, SARM1 rapidly activates and inactivates primarily due to Nam accumulation. 
Figure 11c Cytosolic NAD consumption in axotomy and control models. In the axotomy 
model, there are two major NAD consumption phases. The control demonstrates stable 




Figure 11d Presence of ADPR and cADPR in axotomy and control models. The 
axotomy model demonstrates two rises in ADPR and cADPR concentrations, whereas 
there are no rises observed in the control model. cADPR levels are also maintained longer 
than ADPR levels due to the more stable nature of the molecule. 
Figure 11e NAD presence in the mitochondria and cytosol in axotomy and control models. The 
axotomy model demonstrates the release of mitochondrial NAD into the cytosol via mPTP 
opening causing a late rise in cytosolic NAD. The control model shows steady levels of both 




Figure 11f Decline in ATP levels observed following axotomy. The control demonstrates 
stable ATP levels over time as the model solves for a steady state with given initial conditions. 
Figure 11g Increase in cytosolic calcium levels following axotomy. The inflection point of 
the cytosolic calcium curve for the axotomy model indicates opening of the L-type VGCCs. 
Figure 11h Degeneration time course of axotomy model. Degeneration is completed at 




Figure 12a Mitochondrial and cytosolic calcium in the SARM1 knockout of the axotomy 
model are comparable to the control model. 





Figure 12c No generation of ADPR and cADPR in the SARM1 knockout of the axotomy 
model. 
Figure 12d Cytosolic calcium in the SARM1 knockout of the axotomy model is 




Figure 12e Main figure shows degeneration in the SARM1 knockout of the 
axotomy model is comparable to the control model. Inset shows degeneration of 
the control model due to initial conditions.  
Figure 13a Main figure shows presence of SARM1 in the Nmnat2 knockout of the 
control model (no axotomy) is comparable to the axotomy model. Inset shows presence of 




Figure 13b Main figure shows decrease in NAD in the Nmnat2 knockout of the 
control model (no axotomy) is comparable to the axotomy model. Inset shows 
cytosolic NAD of the initial axotomy and control models. 
Figure 13c Main figure shows generation of ADPR and cADPR in the Nmnat2 
knockout of the control model (no axotomy) is comparable to the axotomy model. Inset 





Figure 13d Main figure shows ATP levels decline in the Nmnat2 
knockout of the control model (no axotomy) comparable to the 
axotomy model. Inset shows ATP levels in the initial axotomy and 
control models. 
Figure 13e Main figure shows cytosolic calcium in the Nmnat2 
knockout of the control model (no axotomy) is comparable to the 
axotomy model. Inset shows cytosolic calcium in the initial axotomy 





Figure 13f Main figure shows degeneration time course in the Nmnat2 knockout of 
the control model (no axotomy) is comparable to the axotomy model. Onset shows 
the degeneration time course of the initial axotomy and control models. 
Figure 14a Presence of Nmnat in the PHR1 knockout of the axotomy model is comparable to 




Figure 14c Cytosolic NAD in PHR1 knockout of the axotomy model is comparable to the 
control model. 
Figure 14b Main figure shows presence of active SARM1 in the PHR1 knockout of the axotomy model 





Figure 14d No generation of cADPR and ADPR in PHR1 knockout of the axotomy 
model. 





Figure 14f Cytosolic calcium in the PHR1 knockout of the axotomy model are 
comparable to the control model. 
Figure 14g Main figure shows degeneration time course in the PHR1 knockout of 
the axotomy model is comparable to the control model. Inset shows degeneration time 




Figure 15a Active SARM1 in nifedipine treatment is comparable 
to the initial axotomy model. 
Figure 15b Generation of cADPR and ADPR in nifedipine treatment is comparable 
to the initial axotomy model. These species are the primary drivers behind 
mobilization of calcium to the cytosol in nifedipine treatment. 




Figure 15c Difference in cytosolic calcium levels between nifedpipine treatment and the 
initial axotomy model. There is a less pronounced rise in cytosolic calcium in the 
nifedipine treated axotomy model. 
Figure 15d Increases in cytosolic calcium are less pronounced in nifedipine treatment 
compared to the initial axotomy model since there is no contribution to cytosolic calcium 




Figure 15e ATP decline in nifedipine treatment is delayed compared to the initial 
axotomy model. This delay is in part due to the lower levels of cytosolic calcium and 
slower consumption of ATP by calcium ATPases. 
Figure 15f Delayed degeneration time course in nifedipine treatment is observed 




Figure 16a Active SARM1 levels in FK866 treatment are slightly less than levels 
in the initial axotomy model. There is a more pronounced decrease of active 
SARM1 in FK866 treatment around t=40 due to increased levels of Nam. 
Figure 16b Difference in levels of Nam between FK866 treatment and initial 




Figure 16c Difference in cADPR and ADPR levels between FK866 treatment 
and the initial axotomy model. There is a net decrease in both species in the FK866 
treated axotomy model. 
Figure 16d Difference in cytosolic NAD levels between FK866 and the initial 
axotomy model. There is a delayed release of mitochondrial NAD into the cytosol in 




Figure 16e ATP decline in FK866 treatment is delayed compared to the 
initial axotomy model. This delay is in part due to the lower levels of 
cytosolic calcium and slower consumption of ATP by calcium ATPases. 
Figure 16f Increases in cytosolic calcium are less pronounced in FK866 
treatment compared to the initial axotomy model since there is a decrease in 




Figure 16g Delayed degeneration time course in FK866 treatment is observed 
compared to the initial axotomy model due to slower cytosolic calcium 
accumulation. 
Figure 17a Main figure shows mitochondrial and cytosolic NAD levels in mPTP 
inhibition of the axotomy model. There is an early decline in cytosolic NAD, but 
there is no release of mitochondrial NAD to contribute to the cytosolic NAD pool. 





Figure 17b Main figure shows presence of ADPR and cADPR in mPTP 
inhibition of the axotomy model. There is a conserved early generation of these 
cleavage products, but no later rise as observed in the initial axotomy model 
(see inset).  
Figure 17c ATP levels are maintained in mPTP inhibition of the axotomy 




Figure 17d Main figure shows cytosolic calcium rises and recovers in 
mPTP inhibition of the axotomy model. Inset shows cytosolic calcium levels 
in the initial axotomy and control models. 
Figure 17e Main figure shows persistent levels of active SARM1 in 
mPTP inhibition of the axotomy model. Inset shows active SARM1 




Figure 17f Main figure shows degeneration time course in mPTP inhibition 
of the axotomy model is substantially slower compared to the initial axotomy 
model. However, mPTP inhibition is less protective than SARM1 or PHR1 
knockouts due to the early generation of NAD cleavage products by active 
SARM1. Inset shows degeneration time course of axotomy and control 
models. 
Figure 18a Cytosolic calcium diffuses quickly from an initial 
release source over time (s). The release of calcium is assumed to 




Figure 18b Diffusion of calcium from an initial release source 
over space and time. The release of calcium is assumed to be on the 















Figure 18c Spread of active calpain increases over time 

















Figure 18d Spread of active calpain over space and time in the axon unit 
considered. This pattern of spread can be extrapolated to repeating axon units 
along the length of the axon corresponding to initiation of calcium release. 
Figure 18e Cytosolic calcium diffuses rapidly from single release site (AR) 
and maintains high concentrations between 0.1-1 µm in diffusion distance. 
100 µM of calcium release is considered due to only cADPR-activated RyRs 



















Figure 18f Diffusion of cytosolic calcium from a single release site (AR) 
over space and time. 100 µM of calcium release is considered due to only 
cADPR-activated RyRs from cleavage of cytosolic NAD by SARM1.  
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Appendix—MATLAB Script and Full CellDesigner Model 
Equation Script 
function [dX] = JMC_WD_HalfTreateq2( t,X ) 
  
global k Xind B C 
  
dX = zeros(111,1); 
tTreat = 0.1; 
  
if t < tTreat 
    Xind(13) = 0; 
    Xind(30)=0; 
else 
      Xind(13) = 6*B; 
      Xind(30)=0.5*C;  
    
End 
 
if X(11)>500  
     dX(32)=0; 
 else 




if X(32)<0.000001%need if-else because reversal not included in NCX PM loop 
dX(1) = (X(15)*X(2)*k(2) + X(30)*X(2)*k(2) + X(3)*X(21)*k(2) + 
X(3)*X(25)*X(4)*k(2)*k(34) ... 
       + X(3)*X(33)*X(24)*k(2)*k(35)+X(27)*X(1)*X(101)*k(2)*k(37)+... 
       
X(17)*Xind(1)*k(2)+X(13)*k(6)*0.1+Xind(1)*X(76)*k(2)+Xind(1)*X(75)*k(2))... 
        - (X(9) *k(15)*X(1)*X(11)*k(36)+ X(10)*k(16)*X(1)*X(11)*k(36)... 
        +X(94)*X(1)*X(11)*k(36)*k(16)+X(1)*X(26)*k(2)+1);   
else 
    dX(1) = (X(15)*X(2)*k(2) + X(30)*X(2)*k(2) + X(3)*X(21)*k(2) + 
X(3)*X(25)*X(4)*k(2)*k(34) ... 
       + X(3)*X(33)*X(24)*k(2)*k(35)+ 
X(17)*Xind(1)*k(2)+X(13)*k(6)*0.1+Xind(1)*X(76)*k(2)... 
       +Xind(1)*X(75)*k(2)) - (X(9) *k(15)*X(1)*X(11)*k(36)+ 
X(10)*k(16)*X(1)*X(11)*k(36)... 





% Regulation of PMCA by Calmodulin and PKC activation 
dX(53)=X(1)*X(62)*k(26)-X(53)*k(26); %CaM bind Ca 
dX(62)=X(53)*k(26)-X(1)*X(62)*k(26); %Inactive CaM 
dX(51)=X(1)*X(97)*k(29)-X(51)*k(32); %PKC bind Ca 
dX(97)=X(51)*k(32)-X(1)*X(97)*k(29); %Inactive PKC 
if X(1)<1  
    k(26)=0; 




    k(26)=0.01;       
    k(29)=0.01; 
end 
dX(28)=X(93)*k(27)*X(53)-X(28)*(k(30)+X(95)); %active CaM bind PMCA to give 
active PMCA  
dX(93)=X(28)*k(30)-X(93)*k(30)*X(53); %Inactive PMCA 
dX(96)=X(28)*X(95)-X(96)*k(31); %Phosphorylated active PMCA 
  
%NCX (Plasma Membrane) 
if (Xind(1)/X(1)) >= 12000   
    dX(27) = 0.00001 * Xind(2); %rate NCX Ca 
    dX(23) = 0.00004 * Xind(2); %rate NCX Na 
else  
    if  (Xind(1)/X(1)) < 12000 && (Xind(1)/X(1)) > 100  
        dX(27) = 0.0000001 * Xind(2); 
        dX(23) = 0.0000004 * Xind(2); 
    else 
        dX(27) = 0.00000001 * Xind(2); 
        dX(23) = 0.00000004 * Xind(2); 





    dX(26)=0; 
    elseif X(1)>0.7 
    dX(26)=0.1*Xind(18); 
elseif log(X(3)/X(1))<0 




if X(3)<= 0.5  
    dX(21) = -0.00001*X(3); 
    dX(87)=-0.000001*X(3);  
    dX(100)=-0.000001*X(3); 
elseif X(3)>0.5 
    dX(21) = 0.01 * Xind(17); 
    dX(87) =0.01*Xind(17);  




dX(6) = X(4)*k(34)*X(22)*X(3)*k(2) - 
(X(6)*X(34)*X(33)*k(35)*k(34)+X(6)*X(21)*k(34));  
  
if X(3)/X(1) < 5 && X(3)/X(1) >=2.1  
    dX(22) = 0.000015 * Xind(19); %NCLX Na 
    dX(25) = 0.00001 * Xind(19); %NCLX Ca 
else 
    if X(3)/ X(1) >= 1 && X(3) / X(1) < 2.1  
        dX(22) = 0.0000015 * X(19); 
        dX(25) = 0.000001 * Xind(19); 
    else 
        if X(3)/X(1) < 1  
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        dX(22) = -0.00015 * Xind(19); 
        dX(25) = -0.0001 * Xind(19); 
        else 
            dX(22) = 0.00015 * Xind(19); 
            dX(25) = 0.0001 * Xind(19); 
        end 







%Mitochondrial Hydrogen  
dX(8) = (X(33)*k(35)*X(34)*X(6)*k(34)+X(37)*k(35)*Xind(24)*k(38)*X(36)... 
    +X(3)*k(2)*X(33)*k(35)*X(24))... 





dX(33) = (X(37)*X(100)+X(98)*k(9))-(X(33)*k(35)*X(34)... 
    +X(3)*k(2)*X(33)*k(35)*X(24)+X(33)*k(35)*X(99)*X(101)*k(37));  
if X(8)/X(33) < 0.5 && X(3)/ X(1) >= 0.7  
    dX(34) =  0.0001 * Xind(21); %Rate NCXmt (Na/H) 
else 
    if X(8) /X(33) > 0.7 && X(3)/ X(1) < 1  
        dX(34) = 0.00001 * Xind(21); 
    else 
        if X(8) /X(33) >= 1 
        dX(34) = -0.001 * Xind(21); 
        else 
            dX(34) =  0.001 * Xind(21);  
        end 
    end 
end 
  
%Intermembrane Space Hydrogen 




    dX(37)=(X(8)*k(44)*X(56)*(X(90)+X(91)+X(92)))-
(X(37)*k(35)*X(36)*Xind(24)*k(38));... 
end 
%FADH and FADH2 
dX(38) = X(39) * k(12) - X(38) * k(11);  
dX(39) = X(38) * k(11) - X(39) * k(12); 
  
%NAD and NADH 
dX(40) = X(41) * k(14) - (X(40) * k(47)+X(56)*X(87)); %NADHcyt 
 
%LETM1 
if X(33)/ X(8) <= 2 && X(33)/ X(8) >= 1.5  
    dX(24) = 0.0001 * Xind(16); 




    if X(33)/ X(8) < 1.5 && X(33)/ X(8) >= 1  
       dX(24) = 0.00001 * Xind(16); 
       dX(29) = 0.00001 * Xind(16); 
    else 
        if X(33)/ X(8) < 1 
           dX(24) = -0.001 * Xind(16); 
           dX(29) = -0.001 * Xind(16); 
        else 
            dX(24) = 0.001 * Xind(16); 
            dX(29) = 0.001 * Xind(16); 
        end 




dX(3) = (X(1)*k(2)* X(26)) - (X(3)*k(2)*X(21) + ... 
    X(3)*k(2)*X(25)*X(4)*k(34)+X(3)*k(2)*X(33)*k(35)*X(24));  
  
%RyR2 
if X(1) <= 5 %RyR2 active via CaM-Ca 
    dX(7) = X(52) * X(1) * 0.0000000000000000001 - (X(7)*k(2 
    dX(52)=(X(7)*k(2)+X(31)*k(23))-
(X(52)*k(23)*X(47)+X(52)*X(1)*0.0000000000000000001); %inactive RR2 
else 




    %%RyR2 binding Ca and/or cADPR 
    dX(88)=X(7)*X(47)*k(23)-X(88)*k(23); %active RyR2 with cADPR and Ca  
    dX(31)=X(52)*X(47)*k(23)-X(31)*k(48); %RyR2 active by cADPR 
if (X(1) /X(2)) <= 0.008 && (X(1) /X(2)) >= 0  
    dX(15) = 0.1 * (X(7)+X(88)+X(31)); 
else  
    if (X(1) / X(2)) > 0.008  
        dX(15) = 0.0001 * (X(7)+X(88)+X(31)); 
    else 
        dX(15) = 0.0000001 * (X(7)+X(88)+X(31)); 




dX(61)=X(5)*k(19)-X(61) * X(12) * k(1); %inactive IP3Rs 
dX(5) = X(61) * X(12) * k(1)-X(5)*k(19); % creating active channels 
 
if X(1) /X(2) <= 0.008 && (X(1) /X(2)) >= 0  
    dX(30) = 0.01 * X(5); 
else  
    if (X(1) / X(2)) > 0.008   
        dX(30) = 0.0001 * X(5); 
    else 
        dX(30) = 0.0000000001 * X(5); 






dX(12) = Xind(11) * X(14) - k(4) * X(12); 
  
%PLC activation and PLC inactive 
if X(1) <= 6  
    dX(13) = X(1) * X(105) * 0.0000000000000000001-X(13)*k(18); 
    dX(105)=X(13)*k(18)-X(1) *0.0000000000000000001 * X(105); 
else 
        dX(13) = X(1) * k(6) * X(105)-X(13)*k(18); 
        dX(105)=X(13)*k(18)-X(1) * k(6) * X(105); 
end 
  
%Axoplasmic Reticulum Calcium 
dX(2) = (X(1)*X(11)*k(36)*X(9)*k(15)) - (X(15)*X(2)*k(2)+X(30)*X(2)*k(2));  
  
dX(11) = (X(37) * Xind(24) * X(35))- (X(11) * X(9)*k(15) * X(1) + ... 
     X(11) * X(10)*k(16) * X(1)+ X(11) * X(32); 
  
%Cytosolic Sodium  







    dX(4) = 
(X(23)*X(101)*k(37)*X(1)*k(2)+X(6)*k(34)*X(34)*X(33)*k(35)+X(101)*k(37)*X(99)
*X(33)*k(35)... 




%Na+/H+ transporter at PM  
if X(33)/X(98) < 0.6  
    dX(99) =  0.0001 * Xind(21); 
else 
    if X(33) /X(98) > 0.6 && X(33) /X(98)<1 
        dX(99) = 0.00001 * Xind(21); 
    else 
        if X(33) /X(98) >= 1 
        dX(99) = -0.001 * Xind(21); 
        else 
            dX(99) =  0.001 * Xind(21); 
        end 






if X(1) >= 0.2 && X(1) <= 2 
dX(18) = Xind(14) * X(1) * 0.00000000000000000000001 - k(20) * X(18); 
else 
    if X(1) >2 && X(1) <= 30 
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        dX(18) = Xind(14) * X(1) * 0.000001 - k(20) * X(18); 
    else 
    dX(18) = Xind(14) * X(1) * k(5) - k(20) *X(18); 
    end 
end 
  
%Degradation by calpain 
if X(18)<0.00001 
    dX(20)=-0.1*X(18); 
else 
dX(20) = 0.05 * X(18); %Rate degradation by calpains 
end 
dX(16) = -X(20) * X(16); %Intact structural remaining 
dX(19) = X(20)* X(16); %Conversion of intact to degraded  
 
%Cv1.2  
if X(32)<0.000001 %Depolarization activating Cv1.2 
   dX(17) = 0.001 * (Xind(3) - Xind(13)); 
else 
      dX(17) = -k(17)*Xind(3); 
end 
  
%NMNAT transport from soma down axon and its turnover 
if Xind(7)>0 %injury stops NMNAT2 transport 
    dX(43)=-X(77)*X(43);  
    dX(66)=0.001*(X(43)-0.0317); 
else 
dX(43)=Xind(25)*k(24)-X(77)*X(43);  
if X(41)<X(45) %reversal of NMNAT2 actvity depending on NAD and NMN 
    dX(66)=0.001*X(43); 
elseif X(45)>X(41) 




%NAD Biosynthesis (salvage pathway) and consumption 
if X(46)<0.00001 
dX(44)=(X(41)*k(45)*(X(69)+X(106))+Xind(4)*k(28))-X(44)*X(64); %Nam cyt 
else 






    +X(71))+X(41)*k(14)); 
else 
    dX(41)=(X(45)*X(66)+X(40)*k(47)+X(54)*X(87))-(X(41)*(X(69)... 










%ADPR and cyclic ADPR synthesis and degradation 
if X(46)<0.0001 %Dependent on active SARM1 
    dX(47)=-(X(47)*X(72)+X(47)*k(7)); %cADPR 
    dX(48)=X(47)*X(72)-(X(48)*X(74)+X(48)*k(42)); %ADPR 
else 
    dX(47)=X(41)*X(79)-(X(47)*X(72)+X(47)*k(7));  
    dX(48)=(X(47)*X(72)+X(41)*X(78))-(X(48)*X(74)+X(48)*k(42));  
end 
  
%Calicym mobilization altered by ADPR and cADPR 
dX(49)=X(50)*X(1)*k(2)-X(49)*k(2); %TRPM2 by activated by Ca  
dX(65)=X(48)*k(21)*X(50)-X(65)*k(21)*0.01; %TRPM2 activated by ADPR 
dX(59)=X(50)*X(48)*k(21)*X(1)*k(2)-X(59)*k(21)*k(2); %TRPM2 activated by both 
ADPR and Ca 
dX(50)=(X(50)*X(1)*k(2)+X(50)*X(48)*k(21))-X(48)*k(21); %rate for TRPM2 with 
both Ca and ADPR 
if (X(2) /X(1)) <= 100000 && (X(2) /X(1)) >= 100  
    dX(74) = 0.01*(X(49)+X(65)+X(59); 
else  
    if (X(2) / X(1)) < 100  
        dX(74) = 0.0001*(X(49)+X(65)+X(59)); 
    else 
        dX(74) = 0.000000001*(X(49)+X(65)+X(59)); 
    end 
end 
  
%%SARM1 activity inhibited in the presence of NMNAT 
if X(43)<0.0317 %NMNAT2 falls below its initial value 
dX(46)=(X(89)*k(40)+X(111)*k(39))-
(X(46)*k(40)*X(44)+X(46)*k(41)+X(46)*X(102)); %generate active SARM1 
else 
    dX(46)=-(X(46)*k(40)*X(44)+X(46)*k(41)+X(46)*X(102)); 
end 
dX(89)=X(46)*k(40)*X(44)-X(89)*k(40); %inactivation of SARM1 by NAM 
dX(111)=(X(46)*k(41)+X(46)*X(102))-X(111)*k(39); %inactive SARM1 
  
%Rate equations 
dX(9) =0.1 * Xind(15);            %Rate SERCA 
dX(10) =0.001 * X(28);            %Rate PMCA bound by CaM 
dX(14) = 0.00001 * (X(13)-X(51)); %Rate PIP2 to IP3 catalyzed by activated 
PLC and inhibited by active PKC 
dX(20) = 0.05 * X(18);            %Rate degradation by calpains 
dX(35) = 0.00001 * Xind(22);      %Rate ATP Synthase for ADP and Pi 
dX(36) = 0.00004 * Xind(22);      %Rate ATP Synthase for H+ 
dX(42) = 0.00001 *Xind(22);       %Rate ATP synthase for ADP injured 
dX(64)=0.01*(Xind(29)-Xind(30));  %Rate NAM to NMN with FK866 Tx 
dX(69) =0.001*Xind(27);           %Rate NAD to Nam by CD38 
dX(70) =0.001*X(46);              %Rate NAD to Nam by active SARM1 
dX(71) =0.001*Xind(27);           %Rate NAD to cADPR by CD38 
dX(72) =0.001*Xind(27);           %Rate cADPR to ADPR by CD38 
dX(75) =0.001*X(50);              %Rate extracell Ca to cyt Ca by LTPRC2 
active 
dX(76) =0.001*X(49);              %Rate extracell Ca to cyt Ca by TRPM2 
active 
dX(77) =0.001*X(43);              %Rate NMNATaxon consumption by PHR1 
dX(78) =0.001*X(46);              %Rate NAD to ADPR by active SARM 
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dX(79) =0.001*X(46);              %Rate NAD to cADPR by active SARM 
dX(90)=0.001*Xind(39);            %Rate Complex I Hm to Hims 
dX(91)=0.001*Xind(40);            %Rate Complex III Hm to Hims 
dX(92)=0.001*Xind(41);            %Rate Complex IV Hm to Hims 
dX(94)=0.01*X(96);                %Rate phosphorylated active PMCA 
dX(102)=0.01*(X(43));             %Rate NMNAT inhibit SARM...-X(43) or 
X(43)?? 
dX(106)=0.01*Xind(10);            %Rate SIRT2 
dX(107)=0.01*Xind(9);             %Rate NMNAT3 
dX(110)=0.01*Xind(33);            %Rate SIRT5 
end 
 
Initial Conditions (Run) Script 
global k Xind X0 t 
X0 = zeros(111,1);    
Xind = zeros(43,1);  
 
%Initial values for dependent values (all units: uM) 
X0(1) = 0.1;               %Cyt Ca  
X0(2) = 500;               %AR Ca 
X0(3) = 0.2;               %MT Ca 
X0(4) = 8000;              %Cyt Na 
X0(5) = 0.00001;           %Active IP3R 
X0(6) = 6000;              %Na MT  
X0(7) = 0.00001;           %Active RyR2 
X0(8) = 0.3;               %H MT 
X0(11) = 1540;             %ATP 
X0(12) = 0.000001;         %IP3  
X0(13) = 0.000001;         %PLC bound Ca  
X0(16) = 54.9;             %Intact cytoskeleton  
X0(18) = 0;                %Active calpain 
X0(19) = 0;                %Degraded cytoskeleton 
X0(31) = 0;                %Inactive RyR2 (unbind cADPR) 
X0(33) = 0.06;             %H cyt 
X0(37) = 0.16;             %H ims 
X0(38) = 30;               % FADH2*  unsure  
X0(39) = 15;               % FADH* unsure 
X0(40) = 300;              % NADHcyt as seen on wiki 
X0(41) = 500;              % NAD cyt as seen in lit canto 2015 
X0(43) = 0.0317;           %Nmnat2 in the axon (Not KO =0.0317; KO=0) 
X0(44) = 15;               %NAM cyt--estimate (reasonable between  15 and 60) 
X0(45) = 30;               %NMN cyt 
X0(46) = 0;                %SARM active 
X0(47) = 0;                %cADPR 
X0(48) = 0;                %ADPR--estimate very small initial 
X0(49) = 0;                %TRPM2 active 
X0(50) =0.00010;           %TRPM2 inactive 
X0(51) =0;                 %PKC active 
X0(52) =0.5;               %Ryr2 inactive (was 0.024) 
X0(53) =0;                 %CaM active 
X0(54) =4000;              %NADmt pool 
X0(55) =50;                %NMNmt 
X0(56) =400;               %NADHmt 
X0(88) =0;                 %active RR2 with cADPR 
X0(89) =0;                 %inactive SARM by NAM (SARM-NAM) 
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X0(61) =0.051;             %IP3R inactive 
X0(62) =24.706;            %inactive CaM 
X0(68)=0;                 %NAM mt--DNE! (is now DI!) 
X0(28)=0;                 %PMCA bound by CaM 
X0(93)=5.234;             %PMCA nothing bound (inactive) 
X0(96)=0;                 %active PMCA phosphorylated 
X0(97)=0.165;             %PKC inactive 
X0(98)=0.1;               %extracellular hydrogen 
X0(101)=145000;           %extracellular sodium 
X0(105)=1.214;            %PLC without Ca--can go up to 1.5 - 2** 
X0(111)=0.06100;          %inactive SARM1 (initial) 
  
%Initial rates for modifiers 
X0(9) = 0.01;             %rate SERCA 
X0(10) = 0.0001;          %rate PMCA bound  
X0(14) = 0.000001;        %rate PIP2 to IP3 
X0(15) = 0.1;             %rate active RR3 
X0(17) = 0.001;           %rate Cv 1.2 
X0(20) = 0;               %rate degradation by calpains 
X0(21) = 0.001;           %rate mPTP for Ca2+ 
X0(22) = 0.0001;          %rate NCLX for Na (NCXmt) 
X0(23) = 0.0003;          %rate NCX for Na 
X0(24) = 0.0001;          %rate LETM1 for Ca 
X0(25) = 0.0001;          %rate NCLX for Ca (NCXmt) 
X0(26) = 0.001;           %rate MCU 
X0(27) = 0.0001;          %rate NCX for Ca 
X0(29) = 0.0001;          %rate LETM1 for Ca and H 
X0(30) = 0.1;             %rate active IP3R 
X0(32) = 0.001;           %rate Na/K pump for Na only 
X0(34) = 0.0001;          %rate NCXmt for Na/H  
X0(35) = 0.2;             %rate ATP Synthase for ADP and Pi 
X0(36) = 0.8;             %rate ATP Synthase for H+ 
X0(59) =0.010;            %rate TRPM2 activated by both ADPR and Ca 
X0(63) =0.010;            %rate CaM active enhances SERCA acivity 
X0(64) =0.45;             %rate NAM to NMN by NAMPT 
X0(65) =0.00010;          %rate TRPM2 activated by ADPR only 
X0(66) =0.010;            %rate NMN to NAD by NMNAT2  
X0(67) =0.010;            %rate ATP to ADP by NMNAT 
X0(69) =0.000010;         %rate NAD to Nam by CD38 
X0(70) =0.0050;           %rate NAD to Nam by active SARM1  
X0(71) =0.00010;          %rate NAD to cADPR by CD38 
X0(72) =0.000010;         %rate cADPR to ADPR by CD38 
X0(74) =0.010;            %rate ADPR consumed by TRPM2 active 
X0(76) =0.010;            %rate extracell Ca to cyt Ca by TRPM2 active 
X0(77) =0.20;             %rate NMNAT consumption by PHR1 
X0(78) =0.3;              %rate NAD to ADPR by active SARM 
X0(79) =0.1;              %rate NAD to cADPR by active SARM 
X0(80) =0.010;            %rate Nam inhibit active SARM 
X0(87) =0.0010;           %rate mPTP for NADmt to NAD cyt 
X0(90)=0.50;              %rate Complex I Hm to Hims 
X0(91)=0.50;              %rate Complex III Hm to Hims 
X0(92)=0.50;              %rate Complex IV Hm to Hims 
X0(94)=0.10;              %rate active+phosphorylated PMCA 
X0(95)=0.010;             %rate phosphorylation of active PMCA by PKC 
X0(99)=0.01;              %rate Na+/H+ PM 
X0(100)=0.01;             %rate mPTP Hims and Hmt to Hcyt 
X0(102)=0.1;              %rate NMNAT inhibit SARM 
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X0(103)=0.01;             %rate malate dehydrogenase  
X0(106)=0.00001;          %rate SIRT2 
X0(110)=0.00001;         %rate SIRT5 
  
% Initial values for independent variables 
Xind(1) = 1200;          %extracellular calcium 
Xind(2) = 5.086;         %NCX  
Xind(3) = 0.08;          %Cv 1.2  
Xind(4) = 30;            %NAM extracell 
Xind(5) = 30.134;        %malate dehydrogenase  
Xind(7) = A;             %axon cut 
Xind(8) = 3.217;         %LETM1 
Xind(10) = 8.2;          %SIRT2 
Xind(11) = 10000;        %PIP2  
Xind(14) = 1.816;        %Inactive m-Calpain  
Xind(15) = 0.416;        %SERCA  
Xind(16) = 0.0571;       %HCX  
Xind(17) = 5;            %mPTP 
Xind(18) = 0.291;        %MCU  
Xind(19) = 0.143;        %NCLX  
Xind(20) = 8.754;        %Na/K Pump 
Xind(21) = 5.086;        %NA/H exhanger  
Xind(22) = 1.466;        %ATP Synthase 
Xind(24) = 270;          %ADP  
Xind(25) = 7;            %NMNAT2 soma 
Xind(27) = 0.756;        %CD38 
Xind(29) = 0.786;        %NAMPT 
Xind(31) = 0.0892;       %PHR1 
Xind(33) = 1.664;        %SIRT5 
Xind(39) = 10;           %Complex I ETC 
Xind(40) = 10;           %Complex III ETC 
Xind(41) = 10;           %Complex IV ETC 
Xind(43) = 2.857;        %Na+/H+ exchanger at PM 
 
%Initial rates (no modifiers) 
k(1) = 0.001;            %rate IP3R bind IP3 
k(2) = 0.007;            %rate RR3 bind Ca 
k(3) = 0.001;            %rate turnover of H MT 
k(4) = 0.01;             %rate degredation of IP3 
k(5) = 0.001;            %rate CAPN2 bind Ca 
k(6) = 0.001;            %rate PLC bind Ca 
k(7) = 0.006;            %intrinsic degredation rate of cADPR 
k(8) = 0.0000001;        %rate ATP depletion after axon cut 
k(9) = 1e-5;             %passive diffusion of H+ extracellular into cyt  
k(12) = 0.1;             %rate reduction of FADH2 
k(14) = 0.001;           %rate reduciton of NADH (glycolysis) 
k(15) = 0.005;           %rate SERCA bind Ca 
k(16) = 0.005;           %rate PMCA bind Ca 
k(17) = 0.0000000001;    %rate deactivation of Cv1.2 
k(18) = 0.01;            %rate dissociation PLC and Ca 
k(19) = 0.01;            %rate dissociation of IP3 and IP3R 
k(20) = 0.01;            %rate calcium dissociate from CAPN 
k(21) = 0.001;           %rate ADPR complex with TRPM2 
k(22) = 0.0001;          %rate TCA reduce NAD to NADH 
k(23) = 0.01;            %rate cADPR complex with RyR2 
k(24) = 0.001;           %axonal transport of NMNAT soma to NMNAT axon  
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k(25)=0.0001;            %rate NMNcyt to NMNmt 
k(26)=0.01;              %rate Ca bind/unbind CaM 
k(27)=0.01;              %rate active CaM binds PMCA 
k(28)=0.00001;           %rate NAM ext to NAM cyt 
k(29)=0.01;              %rate PKC bind ca 
k(30)=0.01;              %rate dissociation CaM-Ca from PMCA 
k(31)=0.03;              %rate dephosphorylation of PMCA k=30 s-1 
k(32)=0.01;              %rate calcium dissociate from PKC 
k(33)=0.01;              %rate association of calcium with MCU 
k(34)=0.01;              %rate association of Nacyt with NCLX 
k(35)=0.001;             %rate association of Hcyt with LETM1 
k(36)=0.01;              %rate association of ATP with SERCA and PMCA 
k(37)=0.01;              %rate association of Na extra with NCX PM 
k(38)=0.01;              %rate association of ADPR 
k(39)=0.5;               %rate sarm become active  
k(40)=0.01;              %rate NAM bind active SARM 
k(41)=0.00001;           %intrinsic rate of inactivation by active SARM1 
k(42)=0.2;               %intrinsic degradation rate of ADPR 
k(43)=0.0001;            %rate NADmt synthesis 
k(44)=0.01;              %rate Hmt associate with complexes of ETC 
k(45)=0.01;              %NAD association rate 
k(47)=0.0007;            %coupled rate of malate dehydrogenase 
k(48)=0.001;             %rate cADPR dissociate from RyR2  
 
ODE Solver 
options = odeset('NonNegative',1:111); 
disp('in run') 









%Defining reatment states 
 
%Axotomy 
A =1; %Axotomy 
B =0; %Nifedipine 
C =0; %FK866 
JMC_WD_run2 
















dataTreatNif = X; 
  
%FK866 




dataTreatFK866 = X; 
  
% Differences between two models 
TBLdiff = dataDisease - dataBaseline; %axotomy-control 








    
'Active_IP3R','Mitochondrial_Sodium','Active_RR2','H_mito_matrix','Rate_SERCA
','Rate_PMCA','ATP','IP3','PLC_Ca_bound',... 
    
'Rate_PIP2_IP3','Rate_Active_RR3','Intact_Structural','Rate_Cv1_2','Active_Ca
lpain',... 
    
'Degraded_Structures','Rate_Degradation_CAPN','Rate_mPTP','Rate_NCLX_Na','Rat
e_NCX_Na',... 
    
'Rate_LETM1_Ca','Rate_NCLX_Ca','Rate_MCU','Rate_NCX_Ca','PMCA_CaM','Rate_LETM
1_H','Rate_active_IP3R',... 
    
'Active_RR2_bycADPR','Rate_NaK_Pump','Hcyt','NCXmt','Rate_ATPsyn_ADP','Rate_A
TPsyn_H','Hims',... 
    
'FADH2','FADH','NADHcyt','NADcyt','NMNAT2_axon','NAMcyt','NMNcyt','SARM_activ
e',... 
    
'cADPR','ADPR','TRPM2_Active','TRPM2_inactive','PKC_active','RR2_inactive','C
aM_active',... 
    
'NADmt','NMNmt','NADHmt','TRPM2_activeby_Ca_ADPR','IP3R_inactive','CaM_inacti
ve','rateSerca_CaM',... 
    
'rate_NAMPT','rateADPR_activTRPM2','rate_NMNAT2','rate_NMNAT_ATP','rate_CD38_
cleaveNAD','rate_SARMcleaveNAD',... 
    
'rate_CD38_NADtocADPR','rate_cADPRtoADPR_CD38','rate_TRPM2cleaveADPR','rate_T
RPM2_transpCa',... 





    
'rate_CI_Hmt','rate_CIII_Hmt','rate_CIV_Hmt','PMCA_inactive','rate_activPMCAp
hos','rate_phosPKCPMCA',... 
    
'PMCA_phos','PKC_inactive','Hextracell','rate_NAHpm','Naextracell','rate_NMNA
T2inhibSARM',... 




TcalciumDiff = cell(95,1); 
TCaBLDiff = cell(95,1); %%%update! 83 X's 
Tdegtest = cell(95,1); 
TFKtest=cell(95,1); 
TNiftest=cell(95,1); 
for i = 1:95 
    TCaBLDiff(i) = {TCaBL(:,i)}; 
    Tdegtest(i) = {TBLdiff(:,i)}; 
    TFKtest(i)={TFK866diff(:,i)}; 
    TNiftest(i)={TNifdiff(:,i)}; 
end 
  
Example Plot Script  
figure (1) %Plot NADcyt in control and axotomy treatment 
plot(t,dataDisease(:,41),t,dataBaseline(:,41)) 
legend('Axotomy','Control','Location','SouthEast') 
xlabel('Time', 'Fontsize', 10) 
ylabel('Concentration (uM)', 'Fontsize', 10) 
set(gca, 'Fontsize', 10) 
title('Cytosolic NAD+','Fontsize',12) 
 
figure (2) %Plot NADmt in control and axotomy treatment 
plot(t,dataDisease(:,41),t,dataBaseline(:,41),t,dataDisease(:,54),t,dataBasel
ine(:,54)) 
legend('Axotomy NADcyt','Control NADcyt','Axotomy NADmt','Control 
NADmt','Location','SouthEast') 
xlabel('Time', 'Fontsize', 10) 
ylabel('Concentration (uM)', 'Fontsize', 10) 
set(gca, 'Fontsize', 10) 
title('Mitochondrial and Cytosolic NAD+','Fontsize',12) 
 
Reaction-Diffusion Script  
function diffaxonCa_2 % one unit size 10um 
m = 0; 
x=0:0.08:10; %axon unit size (units: um) 
t = [0 0.005 0.01 0.05 0.1 0.5 1 1.5 2]; %units: seconds 
  
sol = pdepe(m,@diffaxonCa_2pde,@diffaxonCa_2ic,@diffaxonCa_2bc,x,t); 
u1 = sol(:,:,1); 
u2 = sol(:,:,2); 
u3 = sol(:,:,3); 
  















    x,sol(9,:,1)) 
 title('Cytosolic Calcium') 
 xlabel('Distance (um)') 





    x,sol(9,:,3)) 
 title ('Active Calpain') 
 xlabel('Distance (um)') 






xlabel('Distance x (um)') 




title('Active Calpain (uM)') 
xlabel('Distance x (um)') 




function [c,f,s] = diffaxonCa_2pde(x,t,u,DuDx)  
%Diffusion Coefficients. units: um2/s 
D1 = 5.30; %Calcium 
D2 = 0.7;  %Inactive calpain 
D3 = 0.5;  %Active calpain 
  
if u(1)>100 %Calpain only bind Ca high concentrations 
a=0.01*u(1)*u(2); %Generation of active calpain 
else 
    a=0; 
end 






c = [1; 1; 1];  
f = [D1; D2; D3] .* DuDx; 
s = [F1; F2; F3];  
% -------------------------------------------------------------- 
  
function u0 = diffaxonCa_2ic(x) %Initial conditions for each species         
%(units:uM) 
u01=2000*exp(-(x-5)^2/0.1); %Calcium 
u02=1.816; %homogenous distribution of inactive calpain  
u03=0; %Active calpain 
u0= [u01; u02; u03]; 
  
% -------------------------------------------------------------- 
function [pl,ql,pr,qr] = diffaxonCa_2bc(xl,ul,xr,ur,t) 
pl = [0; 0; 0]; %No flux/reflecting BC's 
ql = [1; 1; 1];  
pr = [0; 0; 0];  
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